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ABSTRACT 
Lisa D. DiMartino: Implementation and Effectiveness of Triggered Palliative Care Consults 
in Oncology 
(Under the direction of Bryan J. Weiner) 
 
The overall objectives of this research were to: (1) determine whether triggered 
palliative care consultation (TPCC) could achieve effective consult implementation in 
oncology and (2) examine the effect of inpatient palliative care consults on health resource 
use (i.e., hospice discharge and 30-day readmissions).  
We used a mixed-methods research design of two distinct inpatient oncology services 
at UNC Hospital. Data sources included qualitative interviews and secondary data using the 
UNC Palliative Care Clinical Research Database linked to electronic medical record data 
from 2010 to 2016. The first study used a two-case study design of palliative care consult 
implementation in the medical oncology and gynecologic oncology services. Qualitative data 
were collected through in-person interviews with clinicians. Quantitative data on consult 
uptake were used to complement the qualitative findings. The study provided an in-depth 
understanding of organizational contextual factors associated with effective palliative care 
consult implementation and suggested refinements to organizational theory. 
The second study used difference-in-difference regression models to longitudinally 
examine the impact of two TPCC approaches on palliative care consult uptake and 
timeliness. TPCC supported by a single strategy was associated with greater consult uptake 
compared to usual care (aRR 1.45, p<.05), and TPCC supported by multiple strategies was 
iv 
associated with greater consult uptake compared to a single strategy (aRR 2.34, p<.001). 
TPCC did not significantly impact time to consult.  
The third study used multivariate regression with propensity score matching to 
examine associations among inpatient palliative care consultation, hospice use (discharge), 
and 30-day unplanned readmissions. The likelihood of having a 30-day readmission did not 
significantly differ between the palliative care consult and usual care groups. However, the 
palliative care consult group was significantly more likely than usual care to have a hospice 
discharge (aRR = 4.09, p<.001). The predicted probability of readmission was lower when 
palliative care consultation was combined with hospice discharge compared to consultation 
with discharge to non-hospice post-acute care or usual care (p<.001). 
In sum, TPCC improved consult implementation in oncology, and inpatient palliative 
care consults leading to hospice discharge resulted in reduced 30-day readmissions. Health 
care systems should consider the organizational context for implementation to identify 
optimal strategies for integrating palliative care consults into oncology and improving 
outcomes for cancer patients.  
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CHAPTER 1. INTRODUCTION 
Cancer patients, particularly those with advanced disease, often experience high 
symptom burden and costly inpatient care.1-3 Evidence from several randomized controlled 
trials (RCTs) demonstrate the potential of palliative care delivered concurrently with cancer-
directed treatments to improve quality of care and outcomes for patients diagnosed with 
advanced cancer.4-7 Palliative care is often provided as a consult service delivered by a 
multidisciplinary team of clinicians who provide symptom management, clarify goals of 
care, and facilitate collaboration between the oncology provider, patient, and family members 
to identify appropriate next steps in care. Palliative care differs from hospice because it is 
available to cancer patients at any stage of disease and can be provided while still receiving 
life-prolonging therapies. However, although several practice guidelines emphasize the 
importance of integrating palliative care with cancer-directed treatments,7-9 many eligible 
cancer inpatients do not receive palliative care consults. For example, one study conducted at 
a major academic medical center found less than half of cancer inpatients received palliative 
care consultation before in-hospital death,10 while another study showed palliative care 
consults occurred in only 5% of patients hospitalized with advanced head and neck cancer.11 
In addition, recent studies have shown even in highly integrated healthcare systems, cancer 
inpatients do not receive timely palliative care consults (i.e., early during the 
hospitalization).12,13 Thus, important gaps remain in improving the consistency and quality of 
palliative care implementation in inpatient oncology settings.  
2 
According to the American Society of Clinical Oncology,14 clinical triggers that alert 
oncology providers about patients needing palliative care are a promising approach to 
improve implementation. Triggered palliative care consultation (TPCC) is based on 
predetermined screening criteria (i.e., metastatic disease or uncontrolled symptoms). 
Although prior studies have shown that TPCC improves consult implementation in the 
intensive care unit,15 there is limited evidence regarding the impact of TPCC in inpatient 
oncology.14,16,17 In addition, less is known about how inpatient palliative care consults in 
oncology may lead to better clinical outcomes such as reduced hospital readmissions.  
Without improved implementation of palliative care in inpatient settings, the ability to 
realize the benefits of palliative care for cancer patients will continue to fall short, therefore a 
greater understanding of the organizational determinants associated with effective palliative 
care consult implementation in oncology should improve quality and appropriateness of 
care.18 The overall objectives of this dissertation are to determine whether TPCC can achieve 
effective consult implementation in oncology and examine the effect of palliative care 
consults on health resource use. The central hypothesis is that TPCC supported by multiple 
strategies (e.g., training in palliative care skills, clinician prompting, chart review) will result 
in improved consult implementation compared to a single strategy (i.e., written guideline) or 
no strategy and that inpatient palliative care consults (whether triggered or not) result in 
improved health resource use (i.e., greater hospice discharge and reduced 30-day 
readmissions) compared to usual care. The rationale for this research is that with the 
knowledge gained, more effective interventions can be developed that close the palliative 
care implementation gap in oncology and improve outcomes for cancer patients. I will test 
my central hypothesis by pursuing the following specific aims:  
3 
Aim 1: To explore the organizational contextual factors associated with palliative 
care consult implementation across two inpatient oncology settings. (Chapter 4) 
Aim 2: To evaluate the impact of two TPCC approaches on consult implementation in 
inpatient oncology. (Chapter 5)  
Aim 3: To examine the effect of inpatient palliative care consults on health resource 
use (i.e., hospice discharge and 30-day readmissions) in oncology. (Chapter 6) 
The dissertation used a mixed-methods research design of two distinct inpatient 
oncology services at UNC Hospital. The primary data sources included qualitative key-
informant interviews and secondary data using the UNC Palliative Care Clinical Research 
Database linked to UNC Hospital electronic medical records from January 1, 2010, to June 
30, 2016. Aim 1 used a two-case study design of palliative care consult implementation in 
the medical oncology and gynecologic oncology services. Qualitative data were collected 
through in-person interviews with clinicians from the medical oncology, gynecologic 
oncology, and palliative care services. Quantitative data on palliative care consult uptake 
were used to complement the qualitative findings and to gain a comprehensive understanding 
of palliative care consult implementation for each of the cases.19 The analytic approach for 
Aim 2 included difference-in-difference regression models to longitudinally examine the 
impact of TPCC on consult implementation (i.e., uptake and timeliness). The analytic 
approach for Aim 3 included multivariate regression with propensity score matching to 
examine associations among inpatient palliative care consultation, hospice use (discharge), 
and 30-day unplanned readmissions.  
The aims from this dissertation were anticipated to produce the following expected 
outcomes: First, this dissertation would contribute to understanding the organizational 
context of palliative care consult implementation in oncology. Second, this dissertation 
would provide scientific knowledge regarding the effectiveness of TPCC for consult 
4 
implementation as well as the association between palliative care consults and downstream 
health resource use. Through examining the organizational context, implementation 
effectiveness, and clinical outcomes of palliative care consults, the results of this dissertation 
will generate new evidence that will contribute to closing the palliative care implementation 
gap, enhancing processes of care, and maximizing patient outcomes in oncology.  
The sections of this dissertation are organized as follows. Chapter 2 summarizes the 
current literature regarding palliative care, including the case for palliative care in oncology, 
the palliative care implementation gap in oncology, use of TPCC in oncology, and palliative 
care and health resource use in oncology. It concludes with significance and innovation of 
the research, including a discussion of using mixed-methods research and justification for the 
dissertation study design. Chapter 3 provides an overview of the methods used throughout 
the dissertation. It includes the underlying conceptual model on which the research is based, 
a description of the study design and rationale, study setting, data sources, study sample, and 
analytic approaches. Chapters 4-6 are manuscripts corresponding to Aims 1-3, respectively, 
and are intended for submission for peer-reviewed publication. Chapter 7 summarizes the 
findings of this dissertation, its policy relevance, and research gaps.  
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CHAPTER 2. LITERATURE REVIEW  
Cancer Burden in the United States 
In 2017, an estimated 1.7 million new cancer cases in the United States will be 
diagnosed and 600,000 people will die from the disease.1 Although the number of cancer 
survivors in the United States continues to increase with improvements in new treatments, 
approximately one-third of patients who are diagnosed with cancer will succumb to the 
disease.2 The economic impact of cancer in the United States is substantial; the direct costs of 
cancer care is expected to rise from $104 billion in 2006 to nearly $173 billion in 2020, with 
most of the costs attributed to care received during the last year of life.3 Cancer patients near 
the end of life experience overly aggressive care, including costly chemotherapy regimens 
and hospital stays, even though numerous studies indicate spending time in the hospital 
conflicts with care preferences and the desire to be at home.4,5 In fact, expenditures for 
chemotherapy continue to escalate,3 and hospitalizations currently account for the largest 
spending in cancer care.6 In 2009, 4.7 million hospitalizations were due to adult cancer; the 
total costs associated with these hospitalizations was $20.1 billion and accounted for 6% of 
all hospital costs.7 In addition, cancer patients frequent the emergency department for their 
acute care needs, such as uncontrolled pain or respiratory distress, which often result in 
inpatient admissions.8,9 Given the increasing number of individuals living beyond a cancer 
diagnosis, finding ways to improve the quality of care and lower costs of cancer care are an 
urgent priority for policymakers and the U.S. healthcare system.10  
8 
What is Palliative Care? 
Palliative care has the potential to add value and improve quality of cancer care by 
moderating use of less effective high-cost treatments while enhancing supportive services 
and symptom control. Palliative care has been broadly defined by the World Health 
Organization as “an approach that improves the quality of life of patients and their families 
facing the problems associated with a life-threatening illness, through the prevention and 
impeccable assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual.”11 Healthcare providers often equate palliative care with hospice or end-of-life care, 
but they are not synonymous. Although hospice is a type of palliative care, it is available 
only to cancer patients no longer receiving therapy with curative intent and typically begins 
late in a cancer patient’s disease trajectory (less than 6-month prognosis). In contrast, “early” 
palliative care (hereinafter called “palliative care”) is delivered to cancer patients while they 
are still receiving life-prolonging therapies and can begin at any stage of disease, meaning it 
is not just appropriate for patients with advanced-stage cancer. Figure 2.1 illustrates the 
relationship between palliative care and hospice across the cancer disease trajectory, from 
curative to end-of-life care.  
 
 
 
Figure 2.1. Palliative care and hospice across the cancer disease trajectory. 
9 
Inpatient Palliative Care Model  
Palliative care can be provided in the inpatient, outpatient clinic, or home setting. As 
an inpatient service, palliative care can be either a consult service or an inpatient unit 
providing direct patient care. The focus of this dissertation will be solely on the provision of 
inpatient palliative care as a consult service. As a consult service, palliative care may be 
available in certain services or across the entire hospital to provide recommendations for care 
to all involved clinicians. Specialized palliative care consult teams have become increasingly 
common in inpatient settings. The percentage of large academic hospitals that reported 
having a palliative care team rose from 25% in 2002 to nearly all hospitals in 2010.12,13 
Inpatient palliative care consult teams aim to: address symptom management; clarify goals of 
care, including advanced care planning; provide spiritual and psychosocial support; and 
facilitate care coordination between the oncologist, the patient, and family members during 
the patient’s hospital stay. These teams are typically composed of multiple providers 
including physicians, nurses, pharmacists, chaplains, and social workers.14  
The Case for Palliative Care in Oncology 
Cancer patients, particularly those with advanced disease, experience many 
complications associated with their illness, including high symptom burden and poor quality 
of life, resulting in costly inpatient care.15,16 Based on evidence from several landmark 
randomized controlled trials (RCTs),17-19 integration of palliative care with cancer-directed 
treatments can reduce symptom burden and improve outcomes. For example, Temel et al. 
found patients with metastatic non–small cell lung cancer who received palliative care 
experienced improved quality of life (QOL), less aggressive care, and improved survival 
compared to usual care.18 Likewise, Bakitas et al.,17 Zimmermann et al.,19 and Grudzen et 
al.20 have all demonstrated advanced cancer patients who received palliative care experienced 
10 
improved QOL compared to standard cancer care. Most recently, a study by Temel et al. 
showed patients newly diagnosed with incurable lung or gastrointestinal cancer who received 
palliative care experienced greater improvements in QOL and depression compared to those 
who received usual care.21 Integration of palliative care has also been shown to have 
substantial cost savings to the healthcare system, and no study has shown cost to increase.22 
Recent studies by May et al. found inpatient palliative care consult soon after admission can 
shorten length of stay and significantly reduce hospital costs for patients with advanced 
cancer, with earlier consultation during the hospitalization associated with greater cost saving 
effect.23,24 As a result of these findings, the integration of palliative care with traditional 
cancer treatment earlier on in the disease trajectory for patients with advanced cancer or high 
symptom burden has been endorsed as guideline concordant care by the National Consensus 
Project for Quality Palliative Care,25 the American Society of Clinical Oncology,22,26 the 
National Comprehensive Cancer Network,27 and the Institute of Medicine.28,29  
Palliative Care Implementation Gap in Oncology 
Despite the guideline recommendations and known benefits of palliative care, a 
quality chasm exists between what is considered ideal care and what actually occurs for 
cancer patients. Prior studies indicate overall uptake of palliative care is poor, with several 
studies indicating many eligible cancer patients do not receive a referral for palliative care.30-
33 In fact, one study conducted at a major academic medical center found that less than half 
of advanced cancer inpatients received palliative care before in-hospital death,34 while 
another study showed only 16% of cancer patients who died in the hospital received a 
palliative care consult.35 In a large sample of advanced head and neck cancer patients, 
inpatient palliative care consults occurred in only 5% of cases.36 Even among cancer 
inpatients receiving palliative care, adherence to quality indicators for palliative care is 
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suboptimal. One recent study showed that even in highly integrated healthcare systems, 
cancer patients in the inpatient setting do not receive timely palliative care for uncontrolled 
symptoms (i.e., pain or shortness of breath).37  
Implementation of inpatient palliative care consults poses a challenge because it 
occurs within complex hospital settings, requiring substantial coordination and cooperation 
between multidisciplinary teams of clinicians and multiple decision-makers involved in 
patient care. Focusing on the organization-level determinants of inpatient palliative care 
consult implementation rather than the patient- or provider-level ones may clarify the 
underlying context in which implementation occurs. However, no prior studies have 
examined the organization-level determinants associated with effective palliative care consult 
implementation in oncology.38 This knowledge is critical to developing effective 
interventions that close the palliative care implementation gap in oncology.38 To fill this 
research gap, this dissertation examined the organizational context for palliative care consult 
implementation across two inpatient oncology settings (Aim 1). 
Triggered Palliative Care Consultation in Oncology 
A promising organizational approach for promoting palliative care consult 
implementation in oncology may be the use of clinical triggers, which provide a “cue to 
action” and can be used to proactively alert oncologists to patients who should be receiving 
palliative care, thereby enhancing consult use.39 Triggered palliative care consultation 
(TPCC) is based on predetermined screening criteria (i.e., metastatic disease or uncontrolled 
symptoms). Although prior research has shown that TPCC improves consult implementation 
in the intensive care unit,40 there is limited evidence regarding the impact of TPCC in 
inpatient oncology.22,41,42 The few studies examining the use of TPCC in oncology have 
several limitations. For example, Rocque et al. conducted an observational study of TPCC 
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among advanced cancer inpatients. Although this study found TPCC had limited impact on 
palliative care uptake, the study was limited by a small sample size (n=200) and examined 
the use of triggers only in medical oncology.43 Similarly, Kistler et al. conducted a proof-of-
concept study on the use of TPCC in advanced cancer patients and found that patients who 
were randomized to the intervention (TPCC) group were significantly more likely to receive 
a consult compared to usual care (88% vs 18%). However, TPCC did not have a significant 
effect on time to consult.44 Although this study was an RCT, it examined the use of TPCC 
only in one service line, the emergency department.44 Although Adelson et al. found TPCC 
for solid-tumor medical oncology inpatients doubled rates of palliative care consultation 
(41% to 82%), the study had a short duration (3 months) and was primarily descriptive.45 
Therefore, this dissertation is significant because it provided the opportunity to use multiple 
years of data from a large number of hospitalizations to examine the impact of two TPCC 
approaches (single strategy vs. multiple strategies) in two inpatient oncology services—solid-
tumor medical oncology and gynecologic oncology (Aim 2). 
Palliative Care and Health Resource Use in Oncology 
Many cancer patients experience poor symptom control and aggressive treatment near 
the end of their lives, including hospitalizations and emergency department (ED) visits, with 
limited medical benefits.9,15,46,47 Studies have reported high unplanned 30-day hospital 
readmission rates for cancer patients, ranging from 11%48 to 27%.6 Likewise, Obermeyer et 
al. showed approximately of 80% of cancer patients visited the ED in the last 6 months of 
life,49 while Mayer et al. found 77% of cancer patients visited the ED in 2008.9 Reducing 
unplanned 30-day readmissions is important to patients and to healthcare organizations 
seeking to lower healthcare costs and avoid penalties under the federal Hospital 
Readmissions Reduction Program (HRRP).50 Under this program, hospitals are fined for high 
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risk-standardized 30-day readmission rates.51 Cancer hospitals are currently excluded from 
the HRRP because they provide care for a distinct patient population with different risk-
profiles for readmissions compared to other hospitals.47 However, frequent hospital 
readmissions and ED visits remain important for oncology patients and are well-accepted 
indicators of poor-quality care for cancer patients near the end of life.46,52 Although research 
shows hospice care is associated with fewer readmissions among cancer patients,47 
conversations about hospice often do not occur between cancer patients and their providers.2 
As a result, cancer patients frequently do not enroll in hospice or are referred late in the 
disease trajectory.53  
Palliative care has also been shown to decrease hospitalizations and ED visits among 
cancer patients when delivered in outpatient settings.18,54-56 In inpatient settings, palliative 
care reduces the intensity of hospital treatment and thus reduces the cost of hospital care.23,57 
However, less is known about how inpatient palliative care affects readmissions in 
oncology.7,58 For example, O’Conner et al. found inpatient palliative care consultation was 
associated with greater hospice discharge, and a 30-day readmission rate reduction from 15% 
to 10%.50 Similarly, Nelson et al. found readmissions decreased from 1.5 to 0.7 admissions 
per patient in the six months after inpatient palliative care consultation.40 However, neither of 
these studies were focused on the cancer population.  
To date, little is known about how hospitals can best achieve reductions in 30-day 
readmissions in oncology.7,47,59 Studies focusing on the association between of inpatient 
palliative care consultation and both hospice and 30-day readmission outcomes in oncology 
are limited.58 For example, a recent study of ovarian cancer patients who had received 
palliative care services while hospitalized had a significantly higher likelihood of hospice 
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discharge compared to those who did not receive palliative care services, but it did not 
examine readmissions.60 Using a propensity-score matched sample, Paris et al. examined the 
effect of inpatient palliative care consultation on hospice and readmissions within a six-
month study period. Although this study also found cancer inpatients who received a 
palliative care consult were significantly more likely to be discharged to hospice compared to 
usual care, it did not find an effect of palliative care consults on readmissions. However, this 
study only included a sample of 201 patients with gastrointestinal cancers and readmissions 
were not the primary outcome of interest.61 Likewise, Gonsalves et al. examined the effect of 
palliative care consultation in a small sample of 200 patients at a Veterans Affairs Hospital 
and found a significant increase in hospice referrals in the last 30 days of life but no effect on 
readmissions.62 This dissertation contributes to the evidence base by using a large sample of 
hospitalizations across multiple cancer types to examine associations among inpatient 
palliative care consultation, hospice use (discharge), and 30-day unplanned readmissions 
(Aim 3). 
Significance and Innovation 
This dissertation is significant for its potential to close the palliative care 
implementation gap in oncology and ultimately improve outcomes for cancer patients by: 
exploring the organizational contextual factors associated with palliative care consult 
implementation across two inpatient oncology settings—solid-tumor medical oncology and 
gynecologic oncology (Aim 1); examining the effect of TPCC on consult implementation in 
oncology (Aim 2); and examining the effect of inpatient palliative care consults on health 
resource use (i.e., hospice discharge and 30-day readmissions) in oncology (Aim 3). As the 
prevalence of inpatient palliative care programs continues to expand, the findings from this 
dissertation will generate timely scientific evidence that directly contributes to the 
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development of improved interventions for palliative care consult implementation within 
academic hospitals. In sum, this dissertation is significant given the dearth of research 
systematically examining implementation of palliative care consults in oncology and the 
downstream health resource use associated with palliative care consults.  
Moreover, this dissertation uses innovative methodological approaches. Studies of 
palliative care consult implementation often ignore organizational context, which is 
important to consider because palliative care delivery is context-specific and occurs within 
the setting of complex healthcare systems. This dissertation applies the Organizational 
Theory of Innovation Implementation to understand the implementation of palliative care 
consults in oncology. Furthermore, this research extends organizational theory by examining 
the role of formal and informal policies and practices in shaping a strong and sustainable 
implementation climate and subsequent effective innovation implementation. The 
dissertation also uses a novel service (organization)-level treatment and comparison group, 
which provided the opportunity to use innovative econometric approaches to studying the 
impact of two TPCC approaches in the inpatient oncology services within an academic 
hospital. Finally, as Figure 2.2 illustrates, this dissertation research provided a unique 
opportunity to employ a mixed-method study design to understand the organizational 
context, implementation effectiveness, and clinical outcomes of palliative care consults in 
oncology. Mixed-method study designs are increasingly used to understand the process and 
outcomes associated with implementation of healthcare practices.63 Specifically, mixed-
methods designs allow for the ability to get a more comprehensive picture of a research 
phenomenon by using both qualitative and quantitative methodologies. 
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Figure 2.2. Dissertation research design. 
 
 
In mixed-method studies, qualitative and quantitative data may be used together to 
complement and clarify or elaborate on the results of analyses.64 In implementation research, 
collecting qualitative data can be useful to obtain an in-depth understanding of the 
organizational context for healthcare practices while quantitative data derived from 
secondary sources can provide measures of implementation effectiveness and clinical 
outcomes in real-world healthcare settings.  
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CHAPTER 3. STUDY DESIGN AND METHODS 
Overview and Rationale 
This dissertation employed mixed-methods research design to understand the 
organizational context, implementation effectiveness, and clinical outcomes of palliative care 
consults in oncology. Aim 1 used a two-case study design of palliative care consult 
implementation in the medical oncology and gynecologic oncology services. Case study 
methods use mixed-methods to provide an in-depth analysis of the organizational context for 
implementation.1 Consistent with a mixed-methods approach, quantitative data on palliative 
care consult uptake were used to complement the qualitative findings from key-informant 
interviews and to gain a comprehensive understanding of palliative care consult 
implementation for each of the cases.2 In Aim 2, difference-in-difference (DID) estimation 
was used to longitudinally examine the impact of triggered palliative care consultation 
(TPCC) on palliative care consult implementation (uptake and timeliness) after controlling 
for underlying secular trends and other potential biases by identifying a comparison group 
that is similar to the treatment group but is not exposed to the treatment. The DID method is 
well suited for situations where implementation of a new policy or treatment occurs in a real-
world context and randomization is not feasible.3 Aim 3 addresses a challenge often 
encountered in observational studies. Specifically, characteristics may influence both the 
receipt treatment (palliative care consults) and outcomes of interest (hospice discharge and 
readmissions), which contributes to selection bias. To minimize the potential for selection 
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bias, propensity score matching was used to examine associations among inpatient palliative 
care consultation, hospice use (discharge), and 30-day unplanned readmissions.  
Specific Aims and Hypotheses 
Aim 1: To explore the organizational contextual factors associated with palliative care 
consult implementation across two inpatient oncology settings.  
Using the Organizational Theory of Innovation Implementation, this Aim examines 
IPPs, implementation climate, innovation-value fit, and innovation-task fit for 
palliative care consults. 
 
Aim 2: To evaluate the impact of two TPCC approaches on consult implementation in 
inpatient oncology. 
Hypothesis 2a: TPCC supported by a single strategy will be associated with more 
consistent consult implementation (greater uptake) compared to usual care. 
Hypothesis 2b: TPCC supported by a single strategy will be associated with improved 
implementation quality (decreased time to consult) compared to usual care.  
Hypothesis 2c: TPCC supported by multiple strategies will be associated with greater 
consult uptake compared to a single strategy.  
Hypothesis 2d: TPCC supported by multiple strategies will be associated with 
decreased time to consult compared to a single strategy.  
 
Aim 3: To examine the effect of inpatient palliative care consults on health resource use 
(i.e., hospice discharge and 30-day readmissions) in oncology. 
Hypothesis 3a: Inpatient palliative care consults will result in greater discharge to 
hospice care. 
Hypothesis 3b: Inpatient palliative care consults will result in lower 30-day 
readmissions after discharge.  
 
Conceptual Framework 
This dissertation drew on the Klein and Sorra (1996) Organizational Theory of 
Innovation Implementation. Briefly, this theory posits that implementation effectiveness is a 
function of formal implementation policies and practices (IPPs), a positive implementation 
climate, perception that the innovations’ use is congruent with the intended users’ values, and 
the extent to which the innovation fits with organizational workflow (Figure 3.1).4-7  
25 
This theory provided an excellent fit for this dissertation for several reasons. First, it 
is well suited for explaining implementation effectiveness for complex innovations, which 
are practices perceived as new by the users in an organization and require coordinated use of 
multiple organizational members to benefit the organization.5 Palliative care consults in 
inpatient oncology are considered a complex innovation based on the following features: (1) 
the integration of palliative care consults with cancer treatment is an expanding and evolving 
area of interest; (2) use of inpatient palliative care consults is complex, comprising multiple 
providers including physicians, nurses, pharmacists, chaplains, and social workers who 
coordinate care for inpatients receiving palliative care; and (3) implementation of inpatient 
palliative care consults requires extensive coordination between multidisciplinary palliative 
care teams and the oncology clinicians overseeing the care of a patient. Implementation is the 
action of putting the innovation (palliative care consults) to use and occurs after the decision 
to adopt the innovation. Implementation effectiveness describes the quality and consistency of 
the use of an innovation (palliative care consults).10 In contrast, innovation effectiveness 
describes the benefits a health care organization ultimately derives from the implementation 
of an innovation (palliative care consults) and is assessed by measuring clinical outcomes, 
such as hospice use or hospital readmissions.10 This dissertation will apply the Klein and 
Sorra theory to examine both implementation effectiveness (Aims 1 and 2) and innovation 
effectiveness (Aim 3) of palliative care consults. 
The theory emphasizes the role of formal IPPs in the organization, which refer to “the 
array of innovation, implementation, organizational, and managerial policies, practices, and 
characteristics that may influence innovation use.”33 The theory postulates that formal IPPs 
collectively influence implementation through implementation climate. The formal IPPs were 
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operationalized as two TPCC approaches for palliative care consult implementation, 
described in detail later in this chapter. Additionally, this dissertation examined the role of 
informal IPPs (e.g., spontaneous communication and on-the-job training) as potential 
determinants of innovation implementation, which has been largely unexplored.4-9  
  
 
Figure 3.1. Conceptual framework, adapted from Klein and Sorra4,5; Helfrich et al.6; Weiner et al.7  
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foster intended 
users’ values. 
Implementation 
Effectiveness 
 
• Quality and 
consistency of 
innovation use 
within an 
organization. 
Innovation 
Effectiveness 
 
• Benefits 
organization derives 
from innovation 
implementation. 
2
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Implementation climate is the most central construct to the theory and is 
conceptualized as “the collective influence of an organization’s multiple implementation 
policies and practices organizations employ to promote innovation use.”10 It refers to the 
shared perception among targeted organizational members of the “extent to which their use 
of a specific innovation is rewarded, supported, and expected within the organization.”5 In 
this dissertation, implementation climate refers to clinicians’ shared sense that palliative care 
consult use is rewarded, supported, and expected within the oncology services. In general, 
the more this shared sense is developed, the greater likelihood the innovation will be used 
consistently and with high quality. 
A strong climate is necessary but not sufficient for effective innovation 
implementation. The association between implementation climate and implementation 
effectiveness may be moderated by the innovation-values fit and innovation-task fit. 
Innovation-values fit is “the extent to which targeted users perceive that use of the innovation 
will foster (or, conversely, inhibit) the fulfillment of their values,”5 where “values” is defined 
as “concepts or beliefs that pertain to desirable end states or behaviors, transcend specific 
situations, and guide the selection and evaluation of behavior and events.”11 Innovation-task 
fit, which was not originally included in the theory, arose from Helfrich et al.’s6 and Weiner 
et al.’s7 prior research indicating the need to parse out the concept of innovation-value fit as 
encompassing not only normative values but “the extent to which an innovation is 
compatible with work processes, task demands, and organizational capabilities.” Even if the 
climate for innovation implementation is strong, a weak innovation-value fit or innovation-
task fit will result in resistance and impede the organizations’ ability to effectively implement 
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the innovation. Table 3.1 summarizes the operational definitions of the conceptual 
framework constructs used in this dissertation. 
 
Table 3.1. Operationalized Definitions of Conceptual Framework Constructs 
Constructs Operational Definition 
IPPs  Two TPCC approaches for palliative care consult 
implementation. 
Implementation Climate Clinicians’ shared perceptions that the use of palliative care 
consults is rewarded, supported, and expected. 
Innovation-Value Fit Extent to which clinicians perceive that use of palliative care 
will foster the fulfillment of their values. 
Innovation-Task Fit Compatibility of palliative care consults with organizational 
workflow and task demands. 
Implementation 
Effectiveness 
Palliative care consult uptake and timeliness. 
Innovation 
Effectiveness 
Effect of inpatient palliative care consults on health resource 
use (i.e., hospice discharge and 30-day readmissions). 
 
 
Study Setting 
The study was conducted in two distinct oncology services at UNC Hospitals, an 804-
bed acute care facility and National Cancer Institute–designated Comprehensive Cancer 
Center. Gynecologic oncology is composed of teams of clinicians who provide care for 
patients with solid-tumor gynecological cancers. Compared to medical oncology, 
gynecologic oncology is a much smaller service, composed of only eight attending clinicians 
who specialize in gynecologic oncology and a small, tight-knit group of specialty and 
subspecialty residents. In contrast, medical oncology has approximately 26 attending 
clinicians who specialize in solid tumors and a large pool of specialty residents. The teams on 
both services include an attending and several house-staff clinicians (residents and medical 
students).  
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The inpatient palliative care consult service at UNC Hospitals began in 2002. The 
team is multidisciplinary, composed of an attending palliative clinician, two nurse 
practitioners, a social worker, and a chaplain; it supports pain and symptom management, 
spiritual/psychosocial distress, goal setting and decision-making for inpatients at all stages of 
illness and their families. It is available to patients only by referral of the primary treating 
team in the oncology services.  
Description of TPCC Approaches in Inpatient Oncology 
This dissertation examined the impact of two TPCC approaches on implementation of 
palliative care consults. TPCC began in gynecologic oncology in August 2014 and was 
supported by a single strategy—a one-page written guideline describing the clinical criteria 
(e.g., unplanned admission for symptom management, frequent readmissions, malignant 
small bowel obstruction) for initiating a palliative care consult posted in the residents’ work 
area. Oncologists in gynecologic oncology developed the guideline internally, without input 
from palliative care service. In contrast, TPCC in medical oncology began in October 2015 
and was supported by multiple strategies designed by palliative care and oncology clinicians. 
The clinical criteria for triggering a consult included the presence of metastatic disease and 
uncontrolled symptoms. A research coordinator reviewed charts for all medical oncology 
admissions. When a patient met the trigger criteria, the attending palliative care clinician 
prompted attending oncologists to consider a consult. Additional strategies included monthly 
training for residents in palliative care skills of advanced care planning communication and 
dedicated institutional funds for TPCC. Palliative care attending clinicians also functioned as 
champions for promoting PC consultation. Table 3.2 describes the two TPCC approaches 
used in the oncology services. 
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Table 3.2. Formal IPPs for Palliative Care Consult Implementation 
TPCC supported by a single strategy 
Service: Gynecologic Oncology 
Start date: August 2014 
TPCC supported by multiple strategies 
Service: Medical Oncology 
Start date: October 2015 
• One-page written guideline of 
clinical criteria for initiating a consult 
(e.g., uncontrolled pain, nausea, 
vomiting, frequent readmissions). 
• Training of residents in palliative 
care skills 
• Clinician prompting of eligible 
patients by palliative care service. 
• Medical chart review to identify 
patients with advanced cancer (i.e., 
metastatic or uncontrolled symptoms). 
• Institutional funding. 
• Appointed champions from PC. 
 
 
Data Sources 
This dissertation relies on both qualitative and quantitative data sources to accomplish 
its aims. Qualitative data were collected through direct observation of the inpatient medical 
oncology, gynecologic oncology, and palliative care services and in-person interviews with 
their clinicians (attendings, house-staff) from March to May 2016. Quantitative data were 
obtained from three sources: Carolina Data Warehouse for Health (CDW-H), UNC Palliative 
Care Clinical Research Database, and UNC Hospital Cancer Registry. The CDW-H is a 
central data repository containing clinical, research, and administrative data from the UNC 
Healthcare System’s electronic health record system. The CDW-H contains data on patient 
demographics, encounters, and diagnosis codes from UNC Hospital. The data requested 
included age, sex, race, insurance status, date of death, admitting/discharge service, dates of 
service, discharge disposition. Data were obtained for all encounters with an admission 
and/or discharge from the gynecologic oncology and medical oncology inpatient services. 
Only encounters that included a diagnosis of a solid-tumor cancer based on International 
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Classification of Diseases (ICD) 9 and 10 codes were included in the dataset. Appendix A 
provides a complete listing of the ICD-9 and ICD-10 cancer diagnosis codes.  
For the Aim 1 analysis, the CDW-H encounter data were linked to patient-level data from the 
UNC Palliative Care Clinical Research Database, which includes data manually abstracted 
from medical charts for all patients at UNC Hospital who receive a palliative care 
consultation. This data source provided the dates of service and oncology service line in 
which the palliative care consult was initiated. For Aims 2 and 3 analyses, this dataset was 
then augmented with patient-level information on cancer stage at diagnosis and diagnosis 
date obtained from the UNC Hospital Cancer Registry. All datasets were linked using the 
Medical Record Number (MRN), the unique patient identifier for the UNC Health Care 
System. Figure 3.2 summarizes each of the data sources used in this dissertation. 
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Figure 3.2 Dissertation data sources. 
 
 
Study Sample and Inclusion/Exclusion Criteria 
Participants for the qualitative interviews were recruited if they had provided patient 
care in the gynecologic oncology or medical oncology services after the formal 
implementation policies and practices (IPPs) were initiated. Participants were then 
purposively sampled according to their clinical role (e.g., attending, resident, subspecialty 
Dissertation
Data 
Sources
Direct Observation and 
Key-Informant 
Interviews
Organizational context 
(IPPs, climate, 
innovation-value fit, 
innovation-task fit) 
(Aim 1)
UNC Hospital Cancer 
Registry
Cancer stage at 
diagnosis, diagnosis 
date
(Aims 2, 3)
UNC Palliative Care 
Clinical Research 
Database
Dates of service, 
oncology service line 
in which consult was 
initiated
(Aims 1, 2, 3)
CDW-H Data
Medical and gynecologic 
oncology encounters from 
UNC Hospital, patient 
demographics, dates of 
death, ICD diagnosis 
codes 
(Aims 1, 2, 3)
Multiple data sources linked 
using MRNs to construct final 
dissertation analytic dataset 
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resident). For all quantitative analyses, all encounters at UNC Hospital with an admission 
and/or discharge from the medical oncology or gynecologic oncology service with a solid-
tumor cancer diagnosis based on ICD 9 and 10 diagnosis codes documented during the 
hospital encounter from January 1, 2010, to June 30, 2016, were included in the dataset (see 
Appendix A). If multiple palliative care consults occurred during a hospital encounter, only 
the first consult was included in the dataset. If a palliative care consult was initiated in a 
service other than the admitting and/or discharge service (e.g., a palliative care consult 
originated in medical intensive care but the admitting and/or discharge service was medical 
oncology), the consult was excluded. For the Aim 3 study sample, the index admission was 
defined as all eligible encounters included in the sample. Encounters with a discharge status 
of missing, “left against medical advice,” or deceased were excluded as an index admission 
but could be considered a readmission. A readmission could also serve as an index admission 
for later discharge encounters.  
Variables and Measurement 
Aim 1 Qualitative and Quantitative Measures 
A semi-structured interview guide was developed using constructs from the 
Organizational Theory of Innovation Implementation as a guide (Figure 3.1). During the 
interviews, participants were asked to describe training received in palliative care skills 
(IPP), incentives used by the oncology services to encourage clinicians to refer patients for 
palliative care consults (IPP), barriers or disincentives to palliative care consultation 
(implementation climate), criteria used to decide whether to refer a patient for a palliative 
care consult (innovation-task fit), and whether or not palliative care consultation helped 
achieve clinicians’ priorities during the time they were rotating on the service (innovation-
values fit). Participants were also asked whether there were any other major events or 
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changes that occurred in the oncology services in the past year that may have impacted 
palliative care consult implementation. For the interviews with palliative care clinicians, 
questions were rephrased to obtain their perceptions of the oncology services’ palliative care 
consult implementation. A variety of probes were used to elicit thorough responses. All 
interviews were audio-recorded and transcribed verbatim. Appendix B includes the complete 
interview guide used in Aim 1.  
Quantitative data on implementation effectiveness, or palliative care consult uptake, 
was derived from aggregated annual and monthly palliative care consult rates within the 
gynecologic oncology and medical oncology services. We defined uptake as completion of a 
palliative care consult as opposed to making a referral. 
Aims 2 and 3 Outcome Variables 
Table 3.3 summarizes the outcomes and measures for Aims 2 and 3 and the 
corresponding constructs from the conceptual framework. The primary outcome of interest 
for Aim 2 was consistency of palliative care consult implementation, which was measured 
using a binary variable for palliative care consult uptake. Similar to Aim 1, uptake was 
defined as completion of a consult during the encounter. To assess quality of palliative care 
consult implementation, a secondary outcome was time to palliative care consult after 
admission, defined as the number of days between admission and palliative care consultation. 
Using a subsample of encounters that involved a palliative care consult, we explored varying 
definitions of a binary variable for time to consult using clinically meaningful cutoffs: within 
2 days of admission (55% of encounters involving a palliative care consult), within 7 days of 
admission (85%), or 14 days of admission (95%).  
For Aim 3, our primary outcomes of interest were hospice discharge (inpatient or 
home) and 30-day unplanned all-cause readmissions. We defined readmission as an inpatient 
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readmission, including ED visits resulting in an admission, within 30 days of discharge. 
Secondary outcomes included ED visits not resulting in an admission within 30 days of 
discharge and a composite outcome of inpatient readmissions and ED visits within 30 days of 
discharge. We calculated time to readmission as the number of days between the index 
admission discharge date and readmission date.  
Longer travel distance is an obstacle for accessing hospital care.12 Because the data 
sources were unique to one hospital system, readmissions to other hospitals may be missed. 
To minimize the potential for measurement error in the outcomes, we used Hospital Referral 
Region (HRR) as a proxy for travel distance and restricted the sample to encounters with 
resident zip codes in the Durham, NC, HRR and neighboring Raleigh and Greensboro, NC, 
HRRs. (Figure 3.3).  
 
 
Figure 3.3. Hospital referral regions examined in Aim 3 (red dot indicates UNC Hospital). 
 
Briefly, HRRs are regional healthcare markets for specialized medical care that 
require the services of a major referral center.13 The Durham, NC, HRR consists of 15 
hospitals located in central NC, including UNC Hospital; the Raleigh, NC, HRR consists of 
Durham HRR 
Greensboro HRR 
Raleigh HRR 
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15 hospitals; and the Greensboro, NC, HRR consist of 5 hospitals. Admissions for 
chemotherapy or radiotherapy (identified using ICD codes V58.xx and Z51.xx), psychiatry, 
or rehabilitation services were not considered readmissions because these usually indicated a 
planned admission. 
 
Table 3.3. Aims 2 and 3 Outcomes and Measures 
Aim Construct Description Outcome Measure 
2 Implementation 
Effectiveness 
(1) PC Consult Uptake 
(2) Time to PC Consult (within 2 
days, 7 days, or 14 days of 
admission) 
(1) Binary 
1=PC consult 
0=No PC consult 
(2) Binary 
1=PC consult≤2 days 
0=PC consult>2 days 
 
1=PC consult≤7 days 
0=PC consult>7 days  
 
1=PC consult≤14 days 
0=PC consult>14 days 
3 Innovation 
Effectiveness 
(1) Hospice discharge 
(2) Unplanned all-cause 30-day 
readmission 
Primary Outcomes: 
(1) Binary 
1=Hospice discharge 
0= Non-hospice post-acute 
care 
(2) Binary 
1=inpatient readmission w/in 
30 days of discharge 
0=no inpatient readmission 
 
Secondary outcomes: 
(1) Binary 
1=ED visits and inpatient 
readmissions w/in 30 days of 
discharge 
 
0=no ED visit or inpatient 
readmission 
 
(2) Binary 
1=ED visit w/in 30 days of 
discharge 
0=no ED visit 
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Aims 2 and 3 Explanatory Variables 
Table 3.4 summarizes the key explanatory variables and measures for Aims 2 and 3 
and the corresponding constructs from the conceptual framework. For the single strategy vs. 
usual care comparison in Aim 2 (Hypothesis 2a and 2b), we included an indicator variable to 
capture exposure to the single strategy based on admission date (on or after 8/1/2014 through 
9/30/2015), oncology service (gynecologic oncology or medical oncology), and the 
interaction term between these two variables. For the multiple strategies vs. single strategy 
comparison (Hypothesis 2c and 2d), we included an indicator variable to capture exposure to 
the multiple strategy based on admission date (on or after 10/1/2015 through 6/30/2016), 
oncology service, and the interaction term between these two variables.  
For Aim 3, the explanatory variable of interest was a binary variable indicating whether or 
not an encounter involved a palliative care consultation. Encounters that involved a palliative 
care consult were included in the “treatment” group; encounters that did not involve 
palliative care consult were included in the “usual care” group. 
 
Table 3.4. Aims 2 and 3 Key Explanatory Variables and measures 
Aim Construct Description Explanatory Measure 
2 IPPs  (1) TPCC supported by 
single strategy vs usual 
care 
 
(2) TPCC supported by 
multiple strategies vs 
single strategy 
(1) Pre/post TPCC indicator interacted with 
oncology service 
1=post TPCC (8/1/2014-9/30/2015) 
0=pre TPCC (1/1/2010-7/31/2014) 
 
 
(2) Pre/post TPCC indicator interacted with 
oncology service 
1= post TPCC (10/1/2015-6/30/2016) 
0=pre TPCC (8/1/2014-9/30/2015) 
3 Implementation 
Effectiveness 
(1) PC Consult 
uptake 
 
(1) Binary 
1=PC consult (“treatment”) 
0=No PC consult (“usual care”) 
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Aim 2 Covariate Selection 
For Aim 2, demographic and clinical characteristics were included that may be 
associated with the exposure to TPCC supported by a single strategy versus multiple 
strategies and palliative care consult uptake. Patient demographic characteristics were 
extracted from the CDW-H data and included categories for race (White—reference, Black, 
other, missing); sex; insurance status (Medicare—reference, Medicaid, private, other public, 
uninsured, missing). Age was included as a continuous variable in all models.  
Patient clinical characteristics were extracted from the UNC Palliative Care Clinical 
Research Database and CDW-H data. Clinical characteristics included: palliative care 
consultation in a prior hospital encounter (yes or no); hospitalization in the prior 30 days (yes 
or no); length of stay (calculated as number of calendar days between admission and 
discharge dates); discharge status (alive or deceased), and solid-tumor cancer type (digestive, 
breast, bone/joint, soft tissue, skin, head/neck, urological, lung/thoracic, gynecological, 
other/ill defined, central nervous system, missing). Because some patients may have been 
diagnosed with multiple cancers, more than one cancer type could be counted per encounter.  
Because palliative care consultation is available to all hospitalized patients regardless 
of cancer stage, we extracted stage of disease from the UNC Hospital Cancer Registry and 
included stage as a control variable in all models. Stage was based on the American Joint 
Committee on Cancer staging criteria (Stage 0 or I, II or III, IV). The most recent stage 
diagnosed before the hospital admission date was included in the dataset. A 60-day window 
was added to the admission date to ensure all cancers staged soon after the admission date 
were captured. If a patient had multiple staged cancers, only the highest stage of disease was 
included in the dataset. If stage could not be ascertained, it was categorized as “missing.”  
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We assessed comorbidities (0, 1, 2 or more comorbidities) using the Quan et al. 
adaptation of the Charlson comorbidity index which includes both ICD-9 and ICD-10 codes 
and has been validated in inpatient settings.14 Comorbidity ICD-9 and 10 codes were derived 
from the patient’s problem list in the electronic health record system. The comorbidities may 
be added at any time the patient receives care at the institution. We searched the problem list 
for evidence of comorbidities 30 days before and after the admission date to ensure all 
comorbidities present at the time of an encounter were captured. Diagnosis of malignant 
disease and metastatic solid tumor were omitted from the comorbidity index. Appendix C 
provides a complete listing of comorbidity ICD-9 and 10 codes used in this dissertation.  
Aim 3 Covariate Selection 
In Aim 3, these same covariates anticipated to be associated with receipt of palliative 
care consults identified in Aim 2 were used to calculate a propensity score and balance the 
treatment (palliative care consult) and usual care (no palliative care consult) groups. The 
groups were also balanced on oncology service (medical oncology or gynecologic oncology) 
and admission year (2010–2016). Hospice discharge was excluded as a covariate because it is 
an outcome of the treatment and including it would obscure the estimated effect of palliative 
care consults on readmissions.15 The process for calculating the propensity scores are 
described in the next section.  
Data Analysis by Aim 
Aim 1  
Qualitative. Qualitative data were coded and analyzed using codes identified 
deductively based on the conceptual framework (Figure 3.1). All transcripts were 
independently coded by a second analyst with extensive experience in qualitative methods. 
Text was coded using a common codebook and any discrepancies in coding were reconciled 
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after each round of independent coding. Within each service, we assessed the degree to 
which each construct appeared in the data (salience) by counting the text segments assigned 
to the construct’s code, the degree to which the construct positively or negatively affected 
implementation (valence), and the degree to which relationships among the constructs were 
supported in the conceptual framework. We also conducted a cross-case synthesis1 to explore 
whether organizational determinants of palliative care consult implementation varied across 
the service lines. We then analyzed the data for key themes and patterns by each construct. 
Quantitative. Aim 1 monthly and annual rates of palliative care consults were 
calculated by dividing the number of encounters that involved a palliative care consult 
(numerator) by the total number of encounters eligible for a consult (denominator), which 
was defined as all hospital admissions within each of the oncology services. A visual 
representation of annual and monthly trends in palliative care consult uptake was provided in 
the form of graphs.  
Aim 2 
For Aim 2, two difference-in-difference (DID) regression models were estimated. The 
first compared changes in outcomes before (1/1/2010–7/31/2014) and after (8/1/2014–
9/30/2015) TPCC in gynecologic oncology (single strategy) to changes over the same time 
period in medical oncology (usual care). The second compared outcomes before (8/1/2014–
9/30/2015) and after (10/1/2015–6/30/2016) TPCC in medical oncology (multiple strategies) 
to changes over the same time period in gynecologic oncology (single strategy). The analysis 
of time to palliative care consult was restricted to admissions with a palliative care consult. 
For each comparison, we estimated separate models for palliative care consult within 2 days, 
7 days, or 14 days of admission (6 models total). The unit of analysis was the discharge 
encounter.  
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We estimated the adjusted relative risk (aRR) and 95% confidence intervals (CI) of 
palliative care consult uptake and time to palliative care consult using modified Poisson 
regression. This method has been shown to estimate the RR consistently and efficiently even 
in small samples.16 Robust standard errors clustered at the patient-level were used to account 
for autocorrelation across encounters, because some patients may have had multiple 
hospitalizations. The binary outcomes for Aim 2 were modeled individually using the 
following DID equation: 
 
Count(μi) = exp(logLengthOfStayi + β0 + β1Timet>TPCC + β2 Servicei + 
β3Timet >TPCC*Servicei + Xit) 
 
where i indicates the encounter and t indicates time and μi = 1 and 0 otherwise. Associated 
with μi is a vector “X” of patient demographic and clinical covariates and year (2010–2016) 
as a continuous variable. The right-hand side of the equation also includes the log of length 
of stay as an exposure, or offset variable, to account for different observation periods. The 
effect of interest is identified by β3 which estimates the effect of TPCC on the probability of 
the outcome for inpatients with solid-tumor cancer admitted and/or discharged from the 
oncology services. 
For the DID estimates to be valid and unbiased, the assumption of parallel trends 
must be met. For the DID estimates to be valid and unbiased, the assumption of parallel 
trends must be met. Briefly, this means the trends in palliative care consult uptake between 
the oncology services were the same prior to TPCC.3 We tested for this assumption using 
data prior to the implementation of any TPCC strategies: 1/1/2010 to 12/31/2013. We 
estimated a modified Poisson regression model that controlled for the same demographic and 
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clinical characteristics as the models for the primary analyses in addition to: a linear time 
trend (admission date as a continuous variable), an indicator for oncology service, and the 
interaction between those two variables. Under the parallel trends assumption, the coefficient 
of the interaction should equal zero. We conducted our analyses using Stata version 13.0 
(College Station, TX). All statistical tests were two-tailed with a critical alpha equal to 0.05. 
Aim 3 
To minimize the potential for selection bias, Aim 3 used propensity scores to identify 
encounters that did not involve a palliative care consult but were comparable to encounters 
that did involve a palliative care consult based on the aforementioned observed covariates.15 
A modified Poisson regression model16 with palliative care consult as the outcome and 
observed covariates as predictors was used to calculate propensity scores. Encounters that 
involved a palliative care consult were matched 1:1 to usual care encounters using the nearest 
neighbor with replacement method, which provided the smallest absolute standardized 
difference in covariates between the groups (i.e., <10%). Any covariates with a standardized 
difference greater than 10% were adjusted for in the post-match analysis.  
Using the propensity score matched sample, we estimated the aRR and 95% CIs of 
hospice discharge, discharge, 30-day unplanned all-cause readmission, and secondary 
outcomes (i.e., ED visits and a composite outcome of inpatient readmissions and ED visits) 
using modified Poisson regression models. 
 
Count(μi) = exp(logDaysToDeathi + β0 + β1 PalliativeCareConsulti+ Xi) 
 
where i indicates the encounter and μi = 1 and 0 otherwise (e.g., hospice discharge or 
discharge to non-hospice post-acute care; readmission or no readmission). Associated with μi 
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will be a vector “X” of covariates additionally adjusted for in the post-match analysis. For the 
readmission analysis only, the right-hand side of the equation also includes the log of days to 
death after discharge (number of calendar days between discharge date to death date) as the 
exposure, or offset variable, to account for mortality during the 30-day readmission window. 
The effect of interest is identified by β1, which estimates the effect of palliative care consult 
on hospice discharge and 30-day readmissions for inpatients with solid-tumor cancer 
admitted and/or discharged from the oncology services. 
We used robust standard errors clustered at the patient level. We included hospice 
discharge as a covariate in the model when examining whether the combination of palliative 
care consultation with hospice discharge was associated with lower 30-day readmissions. 
Adjusted predicted probabilities of a 30-day readmission for an encounter were then 
calculated to contrast outcomes for the following clinical scenarios: usual care, palliative 
consultation combined with hospice discharge, and palliative care consultation with 
discharge to non-hospice post-acute care (e.g., home with self-care or intermediate care 
facility). We conducted all analyses using Stata version 13.0 (College Station, TX). All 
statistical tests were two-tailed with a critical alpha equal to 0.05.  
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CHAPTER 4. INFLUENCE OF FORMAL AND INFORMAL IMPLEMENTATION 
POLICIES AND PRACTICES IN PROMOTING PALLIATIVE CARE 
CONSULTATION IN ONCOLOGY: A MIXED-METHODS ANALYSIS 
Overview 
Evidence demonstrates palliative care (PC) delivered concurrently with cancer 
treatment improves patients’ outcomes, yet integration of PC with inpatient oncology is 
lacking. Inpatient PC consult implementation poses a unique challenge because it occurs 
within complex hospital settings. To date, the Organizational Theory of Innovation 
Implementation has contributed important insights regarding the influence of formal 
implementation policies and practices (IPPs) on effective implementation of healthcare 
innovations, however the role of informal IPPs has been largely unexplored. Therefore, using 
PC consultation as a model, we examined formal and informal IPPs as organizational 
determinants of innovation implementation.  
We used a case study design of PC consult implementation in two inpatient settings 
within one academic medical center: medical oncology and gynecologic oncology. We 
completed semi-structured interviews with inpatient medical (n=12) and gynecologic (n=10) 
oncology attending and house-staff clinicians using questions based on the Organizational 
Theory of Innovation Implementation. Quantitative data were used to assess implementation 
effectiveness, defined as aggregated PC consult rates within the oncology services from 
January 2010 to June 2016. We also interviewed four PC clinicians to gain additional 
insights on the organizational context for implementation.  
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Both oncology services exhibited variable rates of PC consult uptake over time, with 
temporal increases. Medical oncology employed multiple formal IPPs such as training and 
clinician prompting to support PC consultation and a top-down approach, yet most clinicians 
were unaware of the IPPs, contributing to a weak implementation climate. In contrast, 
gynecologic oncology employed one formal IPP (a written guideline of clinical criteria for 
initiating a consult) but also relied on multiple informal IPPs such as spontaneous feedback 
and communication; they adopted a bottom-up approach, contributing to broader clinician 
awareness and a strong implementation climate.  
Our results contribute to emerging research on the organizational determinants of PC 
implementation in oncology. They provide empirical support for the influence of formal and 
informal IPPs as facilitators of innovation implementation, suggesting refinements to 
organizational theory. Future research should further investigate the role of formal and 
informal IPPs in shaping a strong and sustainable implementation climate, and subsequent 
effective implementation of innovations. 
Background  
Cancer patients, particularly those with advanced disease, often experience high 
symptom burden and poor quality of life. Evidence from several randomized trials 
demonstrates that palliative care (PC) delivered concurrently with cancer treatment can 
improve quality of care and outcomes.1-3 However, despite numerous practice guidelines 
emphasizing the importance of early PC for cancer patients with advanced disease or high 
symptom burden,4-7 implementation of routine PC in oncology varies across health systems 
and clinical settings. Prior research has indicated that uptake of PC in inpatient oncology 
settings is poor, with several studies finding that fewer than half of eligible cancer patients 
received a PC consult during hospitalization.8-10 
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Implementation of inpatient PC consults poses a challenge because it occurs within 
complex hospital settings, requiring substantial coordination and cooperation between 
multidisciplinary teams of clinicians and multiple decision-makers involved in patient care. 
Using a conceptual framework that focuses on organization-level, rather than patient- or 
provider-level, determinants of inpatient PC consults may clarify the underlying context in 
which implementation occurs. However, limited information exists on organizational 
determinants associated with effective PC consult implementation across different inpatient 
oncology settings.11  
In this study, we used case study methods to examine the context for PC consult 
implementation in two organizational settings (medical oncology and gynecologic oncology 
service lines) located in a single academic medical center. We drew on the Klein and Sorra 
Organizational Theory of Innovation Implementation12,13 as a guide to developing our 
interview guide and interpreting our results. To date, the theory has contributed to important 
insights regarding the influence of organizationally sanctioned formal implementation 
policies and practices (IPPs) on effective implementation of healthcare innovations, however 
the role of informal IPPs has been largely unexplored.12-17 IPPs refer to “the array of 
innovation, implementation, organizational, and managerial policies, practices, and 
characteristics that may influence innovation use.”13 Compared to formal IPPs (e.g., training 
programs; guidelines, or protocols), informal IPPs such as spontaneous communication and 
on-the-job training require less investment in resources and can readily be adapted to the 
organizations’ implementation needs. Informal IPPs may have other favorable 
characteristics, such as natural emergence from consensus among clinicians. However, less 
explicitly defined IPPs with no organizational mandate may have limited influence on 
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innovation implementation. Therefore, using PC consultation in inpatient oncology as a 
model, the purpose of this study was to examine formal and informal IPPs as determinants of 
innovation implementation.  
Methods 
Conceptual Framework 
A complex innovation is a practice that is perceived as new by the users in the 
organization and requires coordinated use of multiple organizational members to benefit the 
organization.13 We considered PC consults in inpatient oncology to be a complex innovation 
based on the following features: (1) the integration of PC consults with cancer treatment is an 
expanding and evolving area of interest; (2) use of inpatient PC consults is complex, 
comprising multiple providers including physicians, nurses, pharmacists, chaplains, and 
social workers who coordinate care for inpatients receiving PC; and (3) implementation of 
inpatient PC consults requires extensive coordination between multidisciplinary PC teams 
and the oncology clinicians overseeing the care of a patient. Implementation is the action of 
putting the innovation (PC consults) to use. The Klein and Sorra Organizational Theory of 
Innovation Implementation12,13 posits that implementation effectiveness is a function of 
formal IPPs, a positive implementation climate, perception that the innovations’ use is 
congruent with the intended users’ values, and the extent to which the innovation fits with 
organizational workflow (Figure 4.1).14,16  
Organizations can employ a variety of formal IPPs to support the use of an 
innovation. IPPs are cumulative, compensatory, and equifinal, meaning the more formal IPPs 
that an organization uses to support the innovation use the better.13,15 The collective influence 
of an organization’s IPPs shapes implementation climate for innovation use.13-15 Climate 
refers to the shared perception among targeted organizational members of the “extent to 
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which their use of a specific innovation is rewarded, supported, and expected within the 
organization.”13 The more this shared sense is developed, the greater likelihood the 
innovation will be used consistently and with high quality. 
A strong climate is necessary, but not sufficient, for effective innovation 
implementation. The association between climate and implementation effectiveness may be 
moderated by the innovation-values fit and innovation-task fit. Innovation-values fit is “the 
extent to which targeted users perceive that use of the innovation will foster (or, conversely, 
inhibit) the fulfillment of their values.”13 Innovation task fit, which was not originally 
included in the theory, arose from Helfrich et al.’s14 and Weiner et al.’s16 prior research 
indicating the need to parse out the concept of innovation-value fit as encompassing not only 
normative values, but “the extent to which an innovation is compatible with work processes, 
task demands, and organizational capabilities.” Even if the climate for innovation 
implementation is strong, a weak innovation-value fit or innovation-task fit will result in 
resistance and impede the organizations’ ability to effectively implement the innovation.  
Study Setting 
The study was conducted in two distinct oncology services at University of North 
Carolina (UNC) Hospitals, an 804-bed acute care facility and National Cancer Institute 
Comprehensive Cancer Center. Gynecologic oncology is composed of teams of clinicians 
who provide care for patients with solid tumor gynecological cancers. Compared to medical 
oncology, gynecologic oncology is a much smaller service, composed of only eight attending 
clinicians who specialize in gynecologic oncology and a small tight-knit group of specialty 
and subspecialty residents. In contrast, medical oncology has approximately 26 attending 
clinicians who specialize in solid tumors and a large pool of specialty residents. The teams on 
both services include an attending and several house-staff clinicians (residents and medical 
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students). The services are characterized by frequent rotation of attending clinicians and 
turnover of residents. For example, attending clinicians rotate every two weeks in medical 
oncology and every eight weeks in gynecologic oncology, while residents and students rotate 
monthly and subspecialty residents in gynecologic oncology rotate on a weekly basis. Each 
subspecialty resident in gynecologic oncology is assigned the primary responsibility for 
overall organization and delegation of patient care during the week they are on rotation. The 
medical center’s inpatient PC team is interdisciplinary, composed of an attending palliative 
physician, two nurse practitioners, a social worker, and a chaplain; it supports symptom 
management, goal setting, and decision-making for inpatients and is available to patients 
only by referral of the primary treating team in the oncology services. 
PC Consult Implementation in Oncology Services 
Starting in August 2014, gynecologic oncology began using a single formal IPP—a 
one-page written guideline describing the clinical criteria (e.g., unplanned admission for 
symptom management, frequent readmissions, malignant small bowel obstruction) for 
initiating a PC consult posted in the residents’ work area. Oncologists in gynecologic 
oncology developed the guideline internally, without input from PC service. Starting in 
October 2015, medical oncology began using multiple formal IPPs, including chart review to 
identify all cancer inpatients with Stage IV disease and uncontrolled symptoms, prompting 
for PC consultation, and monthly training for residents in PC skills of advanced care 
planning communication. PC attending clinicians functioned as champions for promoting PC 
consultation and institutional funding was secured to support these formal IPPs. All of the 
IPPs were led by the PC service, with significant input throughout implementation from 
selected oncology clinicians.  
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Study Design 
This study used a two-case study design of PC consult implementation in the medical 
oncology and gynecologic oncology services. Case study methods use mixed-methods to 
provide an in-depth analysis of the organizational context and is well-suited for studying 
implementation of innovations.18 Specifically, we explored the organizational context for PC 
consult implementation with qualitative data from key-informant interviews (medical 
oncology, gynecologic oncology, and PC clinicians). Consistent with a mixed-methods 
approach, quantitative data on PC consult uptake were used to complement the qualitative 
findings and to gain a comprehensive understanding of PC consult implementation for each 
of the cases.19 We defined uptake as completion of a PC consult (as opposed to making a 
referral). The University of North Carolina Institutional Review Board reviewed and 
approved this study.  
Qualitative Data Collection 
One investigator (LDD) gathered qualitative data through direct observation of the 
inpatient medical oncology, gynecologic oncology, and PC services and in-person interviews 
with their clinicians (attendings, house-staff) from March to May 2016. Interview 
participants were recruited if they had provided patient care in the gynecologic oncology or 
medical oncology services after the formal IPPs were initiated. Participants were then 
purposively sampled according to their clinical role. Interview participants were recruited in-
person and via e-mail and compensated with a $25 gift card for their time. Questions for the 
semi-structured interviews were developed using the Organizational Theory of Innovation 
Implementation as a guide. For example, participants were asked to describe training 
received in PC skills (IPP), incentives used by the oncology services to encourage clinicians 
to refer patients for PC consults (IPP), barriers or disincentives to PC consultation 
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(implementation climate), criteria used to decide whether to refer a patient for a PC consult 
(innovation-task fit), and whether or not PC consultation helped achieve clinicians’ priorities 
during the time they were rotating on the service (innovation-values fit) (see Appendix B). 
Participants were also asked whether there were any other major events or changes that 
occurred in the oncology services in the past year that may have impacted PC consult 
implementation. For the interviews with PC clinicians, questions were rephrased to obtain 
their perceptions of the oncology services’ PC consult implementation. A variety of probes 
were used to elicit thorough responses. All interviews were audio-recorded and transcribed 
verbatim.  
Quantitative Data Collection 
We obtained quantitative data on PC consult uptake from January 2010 to June 2016 
using data from the UNC Palliative Care Clinical Research database. This database includes 
data abstracted from medical charts for all patients who receive PC consultation, including 
dates of service and oncology service line in which the PC consult was initiated. These data 
were then linked to all hospital stays with an admission and/or discharge from the medical 
oncology or gynecologic oncology service with a solid tumor diagnosis based on 
International Classification of Diseases 9 and 10 diagnosis codes documented during the 
hospital stay using data from the Carolina Data Warehouse for Health (a central data 
repository containing clinical, research, and administrative data from the institution 
electronic health record system). If multiple PC consults occurred during a hospital stay, only 
the first consult was included in the dataset.  
Qualitative Analysis 
Using codes identified deductively based on the conceptual framework (Figure 4.1), 
qualitative data were coded and analyzed using Atlas.ti (version 7.0). Two members of the 
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research team (LDD, ASC) independently coded all interview transcripts (nearly 300 pages 
from all three inpatient service lines) using a common codebook and reconciled codes after 
completion of independent coding. Within each service, we assessed the degree to which 
each construct appeared in the data (salience) by counting the text segments assigned to the 
construct’s code, the degree to which the construct positively or negatively affected 
implementation (valence), and the degree to which relationships among the constructs were 
supported in the conceptual framework. We also conducted a cross-case synthesis18 to 
explore whether organizational determinants of PC consult implementation varied across the 
service lines. We then analyzed the data for key themes and patterns by each construct. 
Quantitative Analysis 
PC consult uptake was derived from aggregated PC consult rates within the 
gynecologic oncology and medical oncology services. We calculated monthly and annual 
rates by dividing the number of encounters that involved a PC consult (numerator) by the 
total number of encounters eligible for a consult (denominator), which was defined as all 
hospital admissions within each of the services. We provided visual representation of annual 
and monthly trends in PC consult uptake in the form of graphs. A scatterplot of the monthly 
rates was overlaid with a fractional polynomial prediction plot to provide a flexible summary 
of the relationship. 
Results 
We analyzed data from interviews (N=26) representing three services: 12 from 
medical oncology, 10 from gynecologic oncology, and 4 from PC (Table 4.1). Roles 
represented across the interviews included attending clinicians (N=13), specialty residents 
(N=6), subspecialty residents (N=3), medical students (N=2), and staff (N=2). Interviews 
ranged from approximately 15 to 45 minutes. Results are summarized in Table 4.2. Briefly, 
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both services exhibited temporal increases in PC consult uptake. Medical oncology employed 
multiple formal IPPs to support PC consultation, yet most clinicians were unaware of the 
IPPs, contributing to a weak implementation climate. In contrast, gynecologic oncology 
employed one formal IPP but also relied on multiple informal IPPs, which contributed to 
broader clinician awareness and a strong implementation climate. The interviews with PC 
clinicians generally corroborated the findings in the oncology services.  
Implementation Effectiveness 
Gynecologic oncology and medical oncology services exhibited variable but 
increasing aggregated rates of PC consults over time. Both services had similar annual rates 
of PC consults in 2010, exhibited a decrease between 2011–2012 and 2012–2013, and then 
increased after 2013 (Figure 4.2). Starting in mid-2014, both services met or exceeded the 
national goal of providing PC consults to approximately 10% of all hospital admissions 
(although no benchmark currently exists specific to inpatient oncology).20 Although at first 
glance these trends appear to be a part of a broader trajectory, Figure 4.3 indicates 
gynecology oncology experienced a slight increase in monthly PC consult rates in August 
2014 after initiation of the single formal IPP and maintained roughly similar rates throughout 
the remainder of the study. In contrast, medical oncology experienced a strong upward spike 
in monthly PC consult rates in October 2015 following initiation of multiple formal IPPs but 
immediately afterward exhibited a sharp decline. Below, we explain that these trends in the 
services might be attributed to not only the initiation of formal IPPs but also informal IPPs, 
implementation climate, innovation-task fit, and innovation-values fit for PC consultation. 
Implementation Policies and Practices 
Medical oncology employed multiple formal IPPs to support PC consultation while 
gynecologic oncology employed one formal IPP; however, compared to medical oncology, 
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gynecologic oncology was more apt to use informal IPPs. For example, several participants 
reported frequent spontaneous communication and feedback between gynecologic oncology 
and the PC service. Participants mentioned they were particularly incentivized to use the PC 
service because of its quickness to respond and strong presence in gynecologic oncology. In 
addition, in the absence of a formal training, most PC skills were learned on-the-job through 
informal interactions with the PC service. One resident stated, 
It’s a constant dialogue. I don’t know if it’s truly feedback, but the nurse 
practitioner or the resident, whoever’s here, there’s almost always one of us 
kind of up here on the floor, whoever’s on the OR [operating room], and they 
[palliative care] come by and see our patients, and they sit in our workroom 
with us, and we talk about the patients, and they kind of tell us their thoughts, 
and they ask us clarifying questions. 
Further, champions in gynecologic oncology were also more emergent and informal 
as opposed to appointed. All interview participants identified at least one attending clinician 
whom they considered to be a champion for PC consults, with one participant identifying the 
fellows and residents as emergent champions because they “do a good job at remembering to 
call PC.” Several participants also discussed how the formal IPP (written guideline) was 
developed by subspecialty residents in the service by adopting an informal bottom-up 
approach, which was in contrast to the formal top-down approach to implementation 
observed in medical oncology.  
Despite multiple formal IPPs in medical oncology, only 5 of 12 interview participants 
(all attending clinicians) were aware of the IPPs. Moreover, these participants had only a 
vague understanding about what the IPPs entailed. As one attending clinician commented, 
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“So I don’t know what the automatic trigger is, but I know that a lot of our patients had 
palliative care consults and it was very useful.” Participants in medical oncology interviews 
also discussed the need for more formal IPPs, including feedback mechanisms, training, and 
specific clinical criteria for initiating PC consults. As one resident commented, “So I guess 
kind of the issue is palliative care kind of consults so they’ll come in and they’ll see a patient 
and they’ll give their recs. It’s so separate that there’s not really usually an opportunity for 
feedback in either direction.” In contrast, several interview participants in gynecologic 
oncology were aware of the written guideline and spoke about it in detail; identifying specific 
clinical criteria that would oftentimes trigger a consult, such as frequent admissions or 
presence of recurrent disease.  
Implementation Climate 
Medical oncology employed multiple formal IPPs but most interview participants 
lacked awareness of the IPPs, which contributed to a weak implementation climate. For 
example, few in medical oncology reported that using PC consults was an expectation on the 
service. Similarly, medical oncology participants’ comments indicated PC consultation was 
not always strongly supported, mentioning numerous barriers including limited availability 
of PC resources and increasing complexity of care as possible disincentives to their use. 
Further, consistent with the lack of awareness of the IPPs in medical oncology, participants’ 
clarity about when to use PC consults and whether they had the skills and tools to play their 
part in making referrals was also absent on this service.  
In contrast, gynecologic oncology employed only one formal IPP, instead relying on 
multiple informal IPPs that contributed to broader clinician awareness and a strong 
implementation climate. For example, although referral is ultimately up to the individual 
clinician, gynecologic oncology participants generally reported PC consultation was 
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expected. Likewise, participants’ comments indicated that PC consultation was supported in 
their work, citing few barriers or disincentives. In particular, participants indicated clarity 
about when to use PC consults was strong and mentioned the formal IPP (written guideline) 
contributed to this clarity. Also in contrast to medical oncology, gynecologic oncology 
participants generally reported having the skills and tools to play their part in referring 
patients for consults, although some discussed needing more training and feedback from the 
PC service in this area. 
Across both services, none reported receiving any specific recognition or rewards for 
PC consultation. Most participants mentioned this was not needed; better patient care was 
identified as the primary reward for PC consultation. However, almost all felt supported 
when it came to the logistics surrounding PC consultation (i.e., use of electronic health 
record system for referrals, paging process, talking on rounds). Many participants discussed 
how the electronic health record system made it easier to make PC consult referrals because 
the process was the same for all consult services in the hospital.  
Innovation-Values Fit  
Both services exhibited a strong innovation-value fit for PC consultation. Across 
clinician roles, PC consultation was found to be highly valued and consistent with the 
providing the best patient care possible. As indicated by one attending clinician, “in medical 
oncology, it’s a complex hospital. Our people are sick. You have multiple specialists... 
they’re all key. They’re [palliative care] as key to the team as the thoracic surgeon.” Each 
service had at least one attending state that every oncology inpatient should have a PC 
consult. Some students and residents spoke about the fit of PC consults with their values—
the strong desire to learn and gain new skills—while attending clinicians spoke about the fit 
of PC consults with their commitment to educate residents. Clinicians in both services stated 
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that PC consults were consistent with “keeping the flow open” and being “vested” in a team-
based approach to care for inpatients admitted with complex medical needs. Given that one-
third of interview participants in each service reported receiving some PC training during 
their medical education, clinicians’ strong value for PC consults may have been fostered by 
this prior exposure.  
Although interview participants from the PC service generally echoed the findings 
from medical and gynecologic oncology, several indicated that PC consults may not always 
be consistent with oncologists’ priority for chemotherapy treatment or timely discharge from 
the hospital.  
Innovation-Task Fit 
Both services reported PC consults generally fit well with their organizational tasks 
and workflow. Several themes may explain this finding. First, the main functions of the 
inpatient PC service are to address symptom management and facilitate goals of care 
discussions. Across both services, participants agreed that PC consults added an extra layer 
of support for symptom management; however, in medical oncology the emphasis was 
primarily on managing pain while in gynecologic oncology participants identified multiple 
symptoms that PC consults aided in managing. As stated by this attending clinician, 
I think it’s usually many times symptom management, so if patients are 
having symptoms from their cancer, especially multiple symptoms from their 
cancer, there’s pain and nausea and maybe shortness of breath and the things 
that we know how to do as gynecologic oncologists don’t seem to maybe 
working the best, I think that’s really probably our number one reason why we 
call them is for symptom control and help with that. 
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Likewise, both services considered there to be a strong fit if goals of care discussions 
were needed because clinicians face many competing demands while on-service and lack the 
time to have lengthier goals of care discussions with patients and their families. Participants 
mentioned that PC consults can help to offset this workload, however our findings across the 
services suggest there may be a U-shaped relationship between patient volume and 
innovation-task fit for PC consults. Specifically, some participants mentioned high patient 
volume would promote PC consultation while others commented they would be more likely 
to use PC consults when volume was low because there was “more time to think about 
individual people and some of their broader problems.” Of note, participants often referred to 
goals of care discussions as “end-of-life care” and indicated they were most compatible only 
if a patient was transitioning to hospice, however this finding was more pronounced on the 
medical oncology service. 
Second, both services reported attending clinicians’ preferred roles impacted how 
well PC consults fit in the service, particularly as it relates to goals of care discussions. For 
example, in gynecologic oncology some attending clinicians mentioned wanting to conduct 
goals of care discussions because they are “my patients.” This comment likely reflects that 
all clinicians on the service care for the same spectrum of cancer types. In contrast, because 
attending clinicians in medical oncology specialize in a variety of tumor types, they may be 
in a better position to discuss prognosis for one cancer type but less comfortable discussing 
the outlook of patients with other cancer types represented on the service. Participants 
identified that patient and family preferences may also affect the fit of PC consults but that 
this could be addressed by improving the branding of the PC service. 
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Third, participants in gynecologic oncology reported PC consults were compatible 
with workflow if they were aware the patient was already receiving PC services in the 
outpatient setting. As one attending clinician stated, “I have a number of my patients that I 
have palliative care help take care of as an outpatient… so usually they will call the consult 
and say what is needed.” In contrast, interview participants in medical oncology were more 
apt to report a poor compatibility if they were unaware whether there was continuity of care 
with PC services in the outpatient setting. As one attending clinician expressed,  
Unfortunately what we don’t have yet is a seamless process where the patients 
are getting these things done in the outpatient setting. And maybe they are, but 
I get this problem all the time, where is the documentation? It’s the weekend. I 
can’t reach the primary attending. I have to have these tough conversations 
now with these folks, so I did them. 
Discussion 
Our study provides empirical support for the role of formal and informal IPPs as 
determinants of PC consult implementation in inpatient oncology, suggesting refinements to 
organizational theory. Specifically, despite the medical oncology service’s use of multiple 
formal IPPs, most participants were unaware of the IPPs, which contributed to a weak 
implementation climate. In contrast, the gynecologic oncology service employed only one 
formal IPP and instead relied on multiple informal IPPs, which contributed to broader 
clinician awareness and a strong implementation climate. Innovation-value fit and 
innovation-task fit (moderators of implementation climate and implementation effectiveness) 
were generally strong in both services.  
According to the Organizational Theory of Innovation Implementation, we would 
expect PC consult uptake to be suboptimal in medical oncology, however both services 
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exhibited temporal increases. In fact, despite clinicians’ lack of awareness in medical 
oncology, PC consult uptake increased significantly after the initiation of the formal IPPs in 
October 2015. This disparate finding is surprising and may be attributed to when 
implementation climate was assessed. Specifically, interviews were conducted several 
months after initiation of the formal IPPs in medical oncology and coincided with the 
declining uptake rates in this service observed at the end of the study (Figure 4.3). This 
decline may provide an indication that climate strength in medical oncology weakened over 
time. Accordingly, our findings from the interviews may not accurately reflect the climate 
strength that existed soon after the formal IPPs were initiated. Alternatively, we examined 
the potential for other initiatives occurring in the oncology services that may have impacted 
PC consult implementation. Participants in both oncology services and the PC service were 
asked if such initiatives had occurred in the past year, but there were no activities reported 
that would be expected to impact PC consult implementation. 
These study findings ultimately point to a broader issue: relying solely on 
organizationally sanctioned formal IPPs may not be effective in creating a strong and 
sustainable climate for implementation in busy, complex healthcare organizations such as the 
academic oncology services examined in this study.21 For example, training is a formal IPP 
commonly used by healthcare organizations to promote innovation use, but residents often 
lack the time outside of their clinical responsibilities to attend skills trainings. In addition, 
new groups of residents rotate through the oncology services on a frequent (though 
predictable) schedule. Thus, it may be important for busy healthcare organizations to develop 
mandatory training programs that are offered on a continuous and routine basis.22,23 
 64 
Otherwise, as our findings indicate, training exposure will be minimal and ultimately 
contribute to a weakened implementation climate over time.  
From a theoretical standpoint, our findings support the idea that informal IPPs may 
compensate or substitute for formal IPPs under certain conditions. As we observed in the 
gynecologic oncology service, this may be more likely to occur in smaller healthcare 
organizations where there is greater opportunity for social interaction and information 
sharing. For example, one study found small primary care practices achieved effective 
implementation of the patient-centered medical home using informal care teams rather than 
more formal care coordination.24 Specifically, formal IPPs may influence implementation 
climate and subsequent effective implementation insofar as the targeted users of the 
innovation have the opportunity to develop a shared sense innovation use is expected, 
supported, and rewarded.13 In gynecologic oncology, we found the use of informal IPPs may 
have played a critical role in creating that shared sense and a strong and sustainable 
implementation climate. For example, gynecologic oncology may have exhibited greater 
awareness of the written guideline because the strong presence of informal IPPs in the 
service continually reinforced its enactment. In particular, adopting a bottom-up approach by 
involving clinicians in all roles in development of the guideline created a greater sense of 
ownership, which may have contributed to awareness and a more positive view of the 
guideline. In contrast, informal IPPs may be less likely to substitute for formal IPPs in larger 
organizations, such as medical oncology, where fragmented intra-departmental units have 
limited opportunity for social interaction.25,26 As we observed, medical oncology used 
multiple formal IPPs developed externally by the PC service. The absence of informal IPPs 
in combination with a top-down approach may have undermined clinicians’ awareness of the 
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IPPs, which contributed to a weak shared sense that PC consultation was expected, 
supported, and rewarded. Future research should further investigate the role of formal and 
informal IPPs in shaping a strong and sustainable implementation climate, including the 
interplay between top-down versus bottom-up approaches and subsequent effective 
implementation of healthcare innovations.  
Study Limitations 
This study has several limitations. First, it was conducted at a single academic 
medical center, which limits generalizability. However, case study research, which 
emphasizes depth over breadth, is appropriate for the purposes of theory refinement.27 
Second, interview data were gathered after the initiation of the formal IPPs in both services. 
Therefore, we are unable to provide a longitudinal assessment of how the organizational 
context for PC consults may have changed over time or determine whether the sharp decline 
in PC consult uptake rates in medical oncology observed at the end of the study would persist 
or eventually rebound. Third, the residents we interviewed described implementation climate 
at the time of the interview, however had we interviewed residents soon after they had 
completed the PC skills training in medical oncology we may have found different climate 
perceptions. Finally, although development of quantitative measures of implementation 
climate are underway,25 they have not been fully tested. Thus, we were unable to specify with 
precision how the services compared on this construct. Nevertheless, our study offers 
preliminary evidence for the role of both formal and informal IPPs as determinants of 
innovation implementation.  
Conclusion 
 Consistent with prior studies,14-16,28 we found the Klein and Sorra Organizational 
Theory of Innovation Implementation to be useful for understanding the implementation of 
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innovations in healthcare organizations. Importantly, this study makes a novel contribution 
by refining the theory to suggest IPPs can be conceptualized as formal and informal. This 
study also adds to the small body of implementation research adapting the theory to include 
innovation-task fit to provide an indication of congruence of the innovation with the 
organization and is a critical determinant of implementation.14,16 However, an examination of 
how much the findings from this study are largely a function of other aspects of the theory, 
including readiness to change, management support, and/or resource availability within the 
service, was missing from our analysis and may warrant further investigation.  
From a practical perspective, this study provides an in-depth exploration of the 
organizational context for PC consult implementation in inpatient oncology. To date, the role 
of formal IPPs on innovation implementation has garnered more attention in the innovation 
implementation literature than the role of informal IPPs,12-17 but the findings from this study 
suggest informal IPPs for promoting effective implementation should be encouraged. As the 
number of inpatient PC programs continues to rise, the results from our study may help 
hospitals identify optimal policies and practices to accelerate the integration of inpatient PC 
consults into oncology practice to close the implementation gap and ensure cancer patients in 
need of PC receive these services.  
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Figure 4.1. Organizational Theory of Innovation Implementation (adapted from Klein and 
Sorra, 1996)12,13 
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Figure 4.2. Annual uptake of PC consults, 2010–2016.  
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Figure 4.3. Monthly uptake of PC consults during implementation.  
 
 
Table 4.1. Number and Characteristics of Key-Informant Interview Participants, by Service 
Service Medical Oncology  Gynecologic Oncology  Palliative Care 
Number 12 10 4 
Role 7 Attending Clinicians 
3 Specialty Residents 
2 Medical Students 
4 Attending Clinicians 
3 Subspecialty Residents 
3 Specialty Residents 
2 Attending 
Clinicians 
2 Staff 
Gender 5 Males 
7 Females 
2 Males 
8 Females 
3 Female 
1 Male 
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The blue arrows indicate initiation of the formal IPPs the oncology 
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Table 4.2. Summary of findings by Organizational Theory of Innovation Implementation Constructs 
Service IPPs Implementation 
Climate 
Innovation-Task Fit Innovation-Values Fit Implementation 
Effectiveness 
Gynecologic 
Oncology 
Formal IPP: 
• Written guideline 
describing the clinical 
criteria for initiating a 
consult. (+) 
 
Informal IPPs: 
• Spontaneous 
communication and 
feedback between the 
gynecologic oncology 
service and PC 
service. (+) 
• On-the-job 
training in PC skills. 
(+) 
• Emergent 
champions who 
stepped out of their 
prescribed role to 
advocate for PC 
consultation. (+) 
• ‘Bottom-up’ 
approach to 
implementation. (+) 
Strong climate for PC 
consult implementation 
 
• PC consultation 
was generally 
expected. (+) 
• PC consultation 
was supported. (+) 
• No specific 
recognition or 
rewards for PC 
consultation. (-) 
Strong innovation-
task fit for PC 
consults 
 
• PC consults 
aided in 
managing 
multiple 
symptoms. (+) 
• PC consults 
helped to offset 
clinician 
workload. (+) 
• PC consults 
not always 
compatible with 
clinician 
preferred roles. (-
) 
• PC consults 
compatible if 
patient receiving 
PC services in 
the outpatient 
setting. (+) 
 
Strong innovation-values 
fit for PC consults 
 
• PC consults 
consistent with 
providing best patient 
care. (+) 
• PC consults fit 
with students/residents 
high-intensity value to 
learn. (+) 
• PC consults fit 
with attending 
clinicians high-
intensity value to 
educate house-staff. 
(+) 
Increase in PC 
consult uptake 
Medical 
Oncology 
Formal IPPs:  
• Chart review to 
identify cancer 
patients with 
advanced (i.e. 
metastatic) disease 
and uncontrolled 
symptoms. (+) 
Weak climate for PC 
consult implementation 
 
• PC consultation 
was not an 
expectation. (-) 
• PC consultation 
was not always 
supported. (-) 
Moderate innovation-
task fit for PC 
consults 
 
• PC consults 
primarily help 
with managing 
pain. (+/-) 
Strong innovation-values 
fit for PC consults 
 
• PC consults 
consistent with 
providing best patient 
care. (+) 
• PC consults fit 
with students/residents 
Increase in PC 
consult uptake 
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• Prompting by the 
PC service to relay 
information about 
eligible patients to 
attending clinicians in 
oncology services. 
(+) 
• Training of 
residents in PC skills. 
(+) 
• Appointed 
champions from PC 
service. (-) 
• Institutional 
funding. (+) 
• ‘Top-down’ 
approach to 
implementation. (-) 
• No specific 
recognition or 
rewards for PC 
consultation. (-) 
• PC consults 
helped to offset 
clinician 
workload. (+) 
• PC consults 
compatible if 
hospice was 
needed. (+/-) 
• PC consults 
not always 
compatible with 
clinician 
preferred roles. (-
) 
• PC consults 
not always 
compatible due 
to lack of 
availability of PC 
services in the 
outpatient 
setting. (-) 
high-intensity value to 
learn. (+) 
• PC consults fit 
with attending 
clinicians high-
intensity value to 
educate house-staff. 
(+) 
IPPs: Implementation Policies and Practices 
(+) = positively associated with implementation 
(-) = negatively associated with implementation 
(+/-) = positively and negatively associated with implementation 
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CHAPTER 5. THE IMPACT OF TWO TRIGGERED PALLIATIVE CARE 
CONSULTATION APPROACHES ON CONSULT IMPLEMENTATION IN 
ONCOLOGY  
Overview 
Studies show palliative care delivered concurrently with cancer treatment improves 
outcomes, yet palliative care integration with inpatient oncology is underused. A promising 
approach to improve integration is a triggered palliative care consultation (TPCC). This study 
evaluated the impact of two TPCC approaches on consistency and quality of consult 
implementation, operationalized as uptake and timeliness, on solid tumor medical and 
gynecologic oncology services at an academic hospital.  
The study timeframe was 2010-2016. TPCC in gynecologic oncology began in 2014 
and was supported by a single strategy (written guideline); TPCC in medical oncology began 
in 2015 and was supported by multiple strategies (e.g. training, chart review). Palliative care 
consult information was chart abstracted and linked to hospital encounter data. We compared 
the effect of a single strategy vs. usual care, and multiple strategies vs. a single strategy on 
implementation. Difference-in-differences modified Poisson regression models evaluated 
whether implementation differed after TPCC; we estimated adjusted relative risk (aRR), 
controlling for patient demographic and clinical characteristics.  
Overall, 8.8% of medical oncology and 11.0% of gynecologic oncology inpatient 
encounters involved palliative care consultation. In regression analyses, TPCC supported by 
a single strategy was associated with greater uptake vs. usual care (aRR: 1.45, p<.05), and 
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TPCC supported by multiple strategies was associated with greater uptake vs. a single 
strategy (aRR: 2.34, p<.001). TPCC did not impact consult timing (p>.05).   
Across two inpatient oncology services, TPCC supported by multiple strategies had 
the greatest impact on uptake. How strategies affect sustained use of palliative care consults 
remains to be investigated. 
Introduction 
Earlier integration of palliative care with cancer treatment is associated with 
improved symptom control, reduced intensity of treatment, similar or improved survival, and 
cost savings.1-3 4,5 Despite these known benefits, palliative care is underused; many eligible 
cancer inpatients do not receive a palliative care consultation.6-9 This may be, in part, because 
effective implementation of palliative care consults in oncology is logistically challenging for 
healthcare organizations. Cancer patients are clinically complex and the provision of 
palliative care consults requires coordination between multidisciplinary palliative care and 
oncology providers.  
Although there are currently no clinical guidelines regarding the timing of palliative 
care consultation in inpatient oncology,10 earlier consults have greater benefit and are 
considered an important indicator of high-quality care.11 The American Society of Clinical 
Oncology (ASCO) recommends12 clinical triggers that alert oncology providers about 
patients needing palliative care to improve implementation. Triggered palliative care 
consultation (TPCC) is based on predetermined clinical criteria (e.g., metastatic disease, 
uncontrolled symptoms).13 Although prior research has shown that TPCC improves consult 
implementation in the intensive care unit,14 there is limited evidence regarding the impact of 
TPCC in inpatient oncology.10,12,13  
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We evaluated the impact of two TPCC approaches on consult implementation in two 
distinct inpatient services, solid tumor medical oncology and gynecologic oncology, at 
University of North Carolina (UNC) Hospitals, an 804-bed acute care facility and National 
Cancer Institute–designated Comprehensive Cancer Center. Theory and prior research 
suggest that more strategies to promote use of a clinical practice will result in greater 
implementation.15,16 Therefore, we hypothesized that TPCC supported by multiple strategies 
(e.g., training, clinician prompting, chart review) would be associated with more consistent 
consult implementation (greater uptake) and improved implementation quality (decreased 
time to consult) compared to a single strategy (i.e., written guideline), and that TPCC 
supported by a single strategy would be superior to usual care.  
Methods 
TPCC Approaches 
TPCC in gynecologic oncology began in August 2014 and was supported by a single 
strategy—a one-page guideline using clinical criteria to initiate a consult written by oncology 
clinicians in the service. The criteria included unplanned admissions for management of 
symptoms of uncontrolled pain, nausea or vomiting, and malignant small bowel obstruction, 
or need for decision support evidenced by frequent readmissions, request for hospice, or 
resistance to advanced care planning.  
In contrast, TPCC in medical oncology began in October 2015 and was supported by 
multiple strategies designed by palliative care and oncology clinicians. The clinical criteria 
for triggering a consult included the presence of metastatic disease and uncontrolled 
symptoms. A research coordinator reviewed charts for all medical oncology admissions. 
When a patient met trigger criteria, the attending palliative care clinician prompted attending 
oncologists to consider a consult. Additional strategies included monthly training for 
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residents in palliative care skills of advanced care planning communication, champions from 
palliative care to promote consultation, and dedicated institutional funds for TPCC.  
Data Sources  
We obtained data on palliative care consults from the UNC Palliative Care Clinical 
Research database, which includes data abstracted from medical charts for all patients at 
UNC Hospital who receive a palliative care consultation. This data source provided the dates 
of service and oncology service line in which the palliative care consult was initiated. Using 
unique identifiers, we then linked these data to hospital encounter data obtained from the 
Carolina Data Warehouse for Health (a central data repository containing clinical, research, 
and administrative data sourced from the institution’s electronic health record system). This 
data source provided admitting and discharge service and dates, discharge status, as well as 
clinical and demographic characteristics. The dataset was then augmented with information 
on patient cancer stage at diagnosis obtained from the UNC Hospital Cancer Registry. The 
UNC Institutional Review Board reviewed and approved this study.  
Study Sample 
We included admissions and/or discharges from the medical oncology or gynecologic 
oncology service lines from January 1, 2010, to June 30, 2016, with a solid tumor diagnosis 
based on International Classification of Diseases (ICD) 9 and 10 codes documented during 
the encounter (see Data Supplement). If multiple palliative care consults occurred during an 
encounter, we only included the first one. We excluded 69 palliative care consults that were 
initiated in a service other than the admitting and/or discharge service (e.g., originated in 
medical intensive care, but the admitting and/or discharge service was medical oncology). 
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Outcomes 
The primary outcome, palliative care consult uptake, was a binary variable. We 
defined uptake as completion of a consult during the encounter. To assess quality of 
implementation, a secondary outcome was time to palliative care consult after admission, 
defined as the number of days between admission and palliative care consultation. Using a 
subsample of encounters that involved a palliative care consult, we explored varying 
definitions of a binary variable for time to consult based on the following cutoffs: within 2 
days of admission (55% of encounters involving a palliative care consult), within 7 days of 
admission (85%), or 14 days of admission (95%).  
Independent Variables 
For the single strategy vs. usual care comparison, we included an indicator variable to 
capture exposure to the single strategy based on admission date (on or after 8/1/2014 through 
9/30/2015), oncology service (gynecologic oncology or medical oncology), and the 
interaction term between these two variables. For the multiple strategies vs. single strategy 
comparison, we included an indicator variable to capture exposure to the multiple strategy 
based on admission date (on or after 10/1/2015 through 6/30/2016), oncology service, and 
the interaction term between these two variables.  
Covariates 
Covariates included categories for race (White – reference, Black, other, missing); 
sex; insurance status (Medicare – reference, Medicaid, private, other public, uninsured, 
missing); palliative care consultation in a prior hospital encounter (yes or no); hospitalization 
in the prior 30 days (yes or no); length of stay (number of calendar days between admission 
and discharge dates); discharge status (alive or deceased), and solid tumor cancer type 
(digestive, breast, bone/joint, soft tissue, skin, head/neck, urological, lung/thoracic, 
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gynecological, other/ill defined, central nervous system, missing). Age was included as a 
continuous variable. Stage of disease at diagnosis was based on the American Joint 
Committee on Cancer staging criteria (Stage 0 or I, II or III, IV). If stage could not be 
ascertained, it was categorized as “missing.” We assessed comorbidity (0, 1, 2 or more 
comorbidities) using previously described coding algorithms.17 Comorbidity ICD codes were 
derived from the patient’s problem list in the electronic health record system. The 
comorbidities may be added at any time the patient receives care at the institution. We 
searched the problem list for evidence of comorbidities 30 days before and after the 
admission date to ensure all comorbidities present at the time of an encounter were captured.  
Statistical Analysis 
Within each oncology service, we describe the study sample using proportions for 
categorical variables and means with standard deviations for continuous variables. We 
examined unadjusted changes in the uptake and time to consult outcomes before and after 
TPCC using a Chi-square test for categorical variables and Wilcoxin rank sum test for 
continuous variables.  
Two difference-in-difference (DID) regression models were estimated. The first 
compared changes in outcomes before (1/1/2010–7/31/2014) and after (8/1/2014–9/30/2015) 
TPCC in gynecologic oncology (single strategy) to changes over the same time period in 
medical oncology (usual care). The sample for the single strategy vs. usual care comparison 
included 8,652 admissions. The second compared outcomes before (8/1/2014–9/30/2015) 
and after (10/1/2015–6/30/2016) TPCC in medical oncology (multiple strategies) to changes 
over the same time period in gynecologic oncology (single strategy); this sample for this 
comparison included 2,614 admissions.  
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The analysis of time to palliative care consult was restricted to admissions with a 
palliative care consult: 746 admissions for comparing use of a single strategy vs. usual care 
and 361 admissions for comparing multiple strategies vs. single strategy. For each 
comparison, we estimated separate models for palliative care consult within 2 days, 7 days, 
or 14 days of admission (6 models total). The unit of analysis was the discharge encounter.  
We estimated the adjusted relative risk (aRR) and 95% confidence intervals (CI) of 
palliative care consult uptake and time to palliative care consult using modified Poisson 
regression.18 Robust standard errors clustered at the patient level were used to account for 
autocorrelation across encounters, because some patients may have had multiple 
hospitalizations. In all models, we control for demographic and clinical characteristics listed 
under covariates and a linear time trend (year as a continuous variable). Length of stay was 
included as an exposure variable to account for different observation periods. 
For the DID estimates to be valid and unbiased, the assumption of parallel trends 
must be met. Briefly, this means the trends in palliative care consult uptake between the 
oncology services were the same prior to TPCC.19 We tested for this assumption using data 
prior to the implementation of any TPCC strategies: 1/1/2010 to 12/31/2013. We estimated a 
modified Poisson regression model that controlled for the same demographic and clinical 
characteristics as the models for the primary analyses in addition to a linear time trend 
(admission date as a continuous variable), an indicator for oncology service, and the 
interaction between those two variables. Under the parallel trends assumption, the coefficient 
of the interaction should equal zero. We conducted our analyses using Stata version 13.0 
(College Station, TX). All statistical tests were two-tailed with a critical alpha equal to 0.05.  
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Results 
Demographic and Clinical Characteristics 
Table 5.1 describes the clinical and demographic characteristics of the sample by 
oncology service. We identified a total of 9,760 encounters with an admission and/or 
discharge from the oncology services between January 1, 2010, and June 30, 2016. Of these, 
5,873 (60%) of encounters were from the medical oncology. Compared to medical oncology, 
the gynecologic oncology sample was older and more likely to be White, female, and 
privately insured. The gynecologic oncology sample was also more likely to have had 
palliative care consultation in a prior hospital encounter and have been hospitalized in the 
prior 30 days. The medical oncology sample was more likely to have a diagnosis of Stage IV 
cancer, one or more comorbidities, and a discharge status of deceased (p<.05). 
Unadjusted Changes in Palliative Care Consult Implementation 
Palliative Care Consult Uptake. The unadjusted changes in the outcomes are 
presented in Table 2. Overall, 8.8% (n=515) of medical oncology encounters and 11.0% 
(n=427) of encounters in gynecologic oncology involved a palliative care consult. Within 
each service, there was a significant increase in palliative care consult uptake after TPCC. 
Specifically, TPCC supported by multiple strategies in medical oncology was associated with 
an increase in consult uptake from 7.6% between 1/1/2010 and 9/30/2015 to 18.4% between 
10/1/2015 and 6/30/2016 (p<.05). Similarly, TPCC supported by a single strategy in 
gynecologic oncology was associated with an increase in consult uptake from 9.3% between 
1/1/2010 and 7/30/2014 to 15.3% between 8/1/2014 and 6/30/2016 (p<.05).  
Time to Palliative Care Consult. In medical oncology, the mean number of days from 
admission to palliative care consult decreased significantly after TPCC from 3.8 to 2.8 
(p<.05), however no significant differences in mean number of days were found in 
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gynecologic oncology after TPCC. Likewise, across both services, TPCC did not have a 
significant effect on the timing of consults (i.e., within 2 days, 7 days, or 14 days of 
admission) (p>.05). 
Adjusted Changes in Palliative Care Consult Implementation 
After adjustment for covariates, there was no significant difference in the trends in 
palliative care consult uptake between oncology services prior to TPCC (i.e., assumption of 
parallel trends was met) (p=.20). Tables 3 and 4 show the results from the adjusted DID 
estimates. TPCC supported by a single strategy in gynecologic oncology was associated with 
greater consult uptake compared to usual care (aRR: 1.45, 95% CI: 1.05-2.01, p<.05), and 
TPCC supported by multiple strategies in medical oncology was associated with greater 
consult uptake compared to a single strategy (aRR: 2.34, 95% CI: 1.57-3.49, p<.001). Across 
all comparisons, the DID estimates showed no significant association between TPCC and 
time to consult (p>.05). 
Discussion 
We examined the impact of two TPCC approaches on consult implementation in 
inpatient oncology. We found that TPCC supported by a single strategy was associated with 
greater consult uptake compared to usual care, and TPCC supported by multiple strategies 
was associated with greater consult uptake compared to a single strategy. Although we were 
unable to directly compare use of multiple strategies in medical oncology to usual care, it can 
be inferred from these findings that TPCC supported by multiple strategies would have the 
largest impact on consult uptake. To date, investigations of the use of TPCC for consult 
implementation in oncology inpatient settings are limited;10,12,13 the few extant studies 
examining this issue have reported unclear evidence for TPCC. For example, among 
hospitalized patients with advanced cancer, Rocque et al. found TPCC had minimal impact 
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on consult uptake,20 while Adelson et al. found TPCC doubled rates of consultation.21 
Notably, both studies were limited by small sample sizes, short durations, and being 
conducted only in medical oncology services. No prior studies have considered the relative 
effectiveness of TPCC supported by a single strategy versus multiple strategies, yet this 
information is critical to enhancing the implementation of palliative care consults in 
oncology. Our study advances prior research by examining the impact of TPCC supported by 
a single strategy or multiple strategies in two inpatient oncology services—gynecologic 
oncology and solid tumor medical oncology. In addition, the availability of multiple years of 
data from a large number of hospitalizations allowed for robust DID methods to account for 
underlying secular trends or other events that may have affected palliative care consult 
implementation.19 
Overall, we found 10% of encounters (8.8% in medical oncology and 11.0% in 
gynecologic oncology) involved a palliative care consultation. Our palliative care 
consultation rate was comparable to what has been reported in similar cohorts of hospitalized 
cancer patients,8,22 although variable rates have been reported ranging from 5% of patients 
hospitalized with head and neck cancer23 to 24% in an inpatient gynecologic oncology 
service.24 Notably, there is no benchmark regarding rates of palliative care consultation in 
inpatient oncology. By establishing benchmark criteria, hospitals could leverage this 
information to determine the current rate of palliative care consultation, decide whether 
TPCC is needed, and evaluate the impact of TPCC on uptake.25  
Contrary to our hypothesis, TPCC did not result in earlier timing of consultation that 
would be expected to enhance quality of care outcomes. In fact, among encounters that 
involved a palliative care consult, just over half of encounters across both oncology services 
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involved early palliative care consults (within two days of admission). These findings are 
consistent with a prior study of TPCC for advanced cancer patients in an emergency 
department; that study found patients received palliative care consultation within an average 
of three days of admission and no effect of TPCC on timing.26 Given our findings, any 
improvements in timing resulting from TPCC would have been minimal and required a 
substantially larger sample size to detect any significant differences. Considering earlier 
palliative care consults are considered an important indicator of high-quality care,11 
additional efforts are needed to develop clinical guidelines regarding timing of consultation 
in inpatient oncology and examine the potential impact of quality improvement efforts, such 
as lean methodology,27 to improve timeliness of consults. 
There are several limitations of this study. First, it occurred at a single academic 
hospital with a well-established palliative care service, which limits generalizability. 
Nonetheless, our findings may extend to similar large hospital settings seeking to improve 
implementation of palliative care consults. Second, we lacked data on prior hospice referral 
or do-not-resuscitate status, however we adjusted for several covariates that reflected health 
status, which minimized the likelihood of obtaining biased estimates. Third, the time to 
palliative care consult analysis was conducted in a small subsample of encounters in the 
oncology services, which minimized our statistical power to detect differences across the 
groups. Finally, TPCC may have impacted important aspects of implementation quality that 
we were unable to measure.28 For example, we were unable to assess quality of the consult 
(e.g., provision of both symptom management and advanced care planning, skill with which 
the consult was done). Future research should consider investigating the effect of TPCC on 
these additional quality indicators.  
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Despite these limitations, our study has important implications. Inpatient palliative 
care programs are increasingly available, yet many eligible cancer inpatients do not receive 
palliative care. In light of the recent ASCO guideline12 underscoring that oncology services 
should consider using clinical triggers, our study findings are timely and add to the growing 
evidence base indicating TPCC can promote the use of palliative care for cancer inpatients. 
Of note, a recent National Comprehensive Cancer Center survey suggested that inpatient 
palliative care programs using TPCC may be constrained by workforce limitations in their 
ability to respond to all patients in need.29 When deciding whether to use TPCC and 
standardize delivery of palliative care, clinicians’ desire to provide these services will need to 
be balanced by availability of trained workforce that can deliver quality palliative care. As 
our findings indicate, TPCC supported by multiple strategies had the greatest impact on 
consult uptake, however a single strategy may provide adequate support to improve the 
integration of palliative care in inpatient oncology. How the strategies affect the sustained 
use of palliative care consults remains to be investigated.  
 
 
 
  
 87 
Table 5.1. Study Sample Characteristics, By Oncology Service 
 
Demographic and Clinical Characteristics       
Medical  
Oncology 
(n=5,873) 
Gynecologic 
Oncology 
(n=3,887) 
Age, mean (SD) 57.4 (13.8) 59.4(14.1) 
Race, n (%) 
 Black 
 White 
 Other 
 Missing 
 
1,661 (28.3) 
3,622 (61.7) 
515 (8.8) 
75 (1.3) 
 
984(25.3) 
2,607(67.1) 
212(5.4) 
84(2.2) 
Sex, n (%) 
Female 
 
2,872(48.9) 
 
3887(100.0) 
Insurance, n (%) 
Medicare 
Medicaid 
Other Public 
Private 
Uninsured 
Missing 
 
2,240(38.1) 
1,286(21.9) 
293(5.0) 
1,704(29.0) 
131(2.2) 
219(3.7) 
 
1,638(42.1) 
551(14.2) 
70(1.8) 
1,353(34.8) 
124(3.2) 
151(3.9) 
Cancer Type, n (%) 
Digestive: Yes 
Breast: Yes 
Bone/Joint: Yes 
Soft Tissue: Yes 
Skin: Yes 
Head/Neck: Yes 
Urological: Yes 
Lung/Thoracic: Yes 
Gynecological: Yes 
Other/Ill Defined: Yes 
CNS: Yes 
Missing: Yes 
 
2,185(37.2) 
700(11.9) 
1,532(26.1) 
245(4.2) 
257(4.4) 
336(5.7) 
484(8.2) 
2,326(39.6) 
49(0.8) 
1,151(19.6) 
1,017(17.3) 
358(6.1) 
 
1,159(29.2) 
46(1.2) 
110(2.8) 
43(1.1) 
23(0.6) 
0(0) 
69(1.8) 
260(6.7) 
2,618(67.3) 
431(11.1) 
76(1.9) 
452(11.6) 
Cancer Stage at Diagnosis, n (%) 
0 or I 
II or III 
IV 
Missing 
 
513(8.7) 
1,596(27.2) 
1,792(30.5) 
1,972(33.6) 
 
585(15.1) 
1,218(31.3) 
531(13.7) 
1,553(39.9) 
Comorbidities: Charlson Index, n (%) 
0 
1 
>=2 
 
4,123(70.2) 
1,087(18.5) 
663(11.3) 
 
3,078(79.2) 
519(13.4) 
290(7.5) 
Length of Stay, mean days (SD) 6.1(5.7) 6.4(6.7) 
PC consultation in a prior hospital encounter, n (% 
Yes) 
200(3.4) 269(6.9) 
Hospitalized in Prior 30 days, n (% Yes) 1,304(22.2) 988(25.4) 
Discharge Status, n (% Deceased) 235(4.0) 64(1.7) 
Abbreviations: PC, Palliative care, SD, standard deviation, CNS, Central Nervous System 
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Table 5.2. Unadjusted Changes in Palliative Care Consult Implementation 
 
 
 
 
 
 
 
Outcome Measures 
Medical Oncology  Gynecologic Oncology 
 
 
Before 
Initiation of 
TPCC 
(1/1/2010-
9/30/2015) 
(n=5,260) 
 
 
 
After Initiation 
of TPCC 
(10/1/2015-
6/30/2016) 
(n=613) 
  
 
Before 
Initiation of 
TPCC 
(1/1/2010-
7/30/2014) 
(n=2,779) 
 
 
 
After Initiation 
of TPCC 
(8/1/2014-
6/30/2016) 
(n=1,108) 
PC consult uptake, n (% Yes)  
402 (7.6) 
 
113 (18.4)‡ 
  
258 (9.3) 
 
169 (15.3)‡ 
Time to PC consult, mean 
days from admission (SD)*ᵃ 
3.8 (4.2) 2.8 (3.2)†  4.5 (6.5) 3.7 (5.6) 
PC consult within 2-days, n 
(% Yes)* 
 216(53.7) 67(59.3)  141(54.5) 102(60.4) 
PC consult within 7-days, n 
(% Yes)* 
345(85.8) 104(92.0)  221(85.7) 149(88.2) 
PC consult within 14-days, n 
(% Yes)* 
388(96.5) 112(99.1)  240(93.0) 162(95.9) 
*Calculated only for subsample of encounters that involved a palliative care consult 
ᵃCalculated using Wilcoxin rank sum test 
Abbreviations: PC, palliative care, TPCC, triggered palliative care consultation, SD, standard deviation 
†: Significant at the p=.05 level 
‡: Significant at the p=.01 level 
 
 
Table 5.3. Changes (difference-in-difference) in Palliative Care Consult Implementation 
Associated with TPCC: Single Strategy vs. Usual Care 
 
 
Outcome Measures 
 
 
 
N 
 
 
Adjusted 
Relative Risk 
 
95% 
Confidence 
Interval 
PC Consult Uptake 8,652 1.45‡ 1.05-2.01 
Time to PC Consult (percentile) 746   
Within 2-days (55th)  1.13 0.69-1.87 
Within 7-days (85th)  0.96 0.69-1.34 
Within 14-days (95th)  0.97 0.74-1.28 
Abbreviations: PC, palliative care, TPCC, triggered palliative care consultation 
†: Significant at the p=.05 level 
‡: Significant at the p=.01 level 
NOTE. All regression analyses controlled for differences in age, race, sex, insurance, cancer type, cancer 
stage, PC consultation in a prior hospital encounter, hospitalization in prior 30 days, comorbidities, 
discharge status, and a linear time trend. Length of stay was included as an exposure variable. 
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Table 5.4. Changes (difference-in-difference) in Palliative Care Consult Implementation 
Associated with TPCC: Multiple Strategies vs. Single Strategy 
 
 
Outcome Measures 
 
 
 
N 
 
 
Adjusted 
Relative Risk 
 
95% 
Confidence 
Interval 
PC Consult Uptake   2,614 2.34‡ 1.57-3.49 
Time to PC Consult (percentile) 361   
Within 2-days (55th)  1.23 0.67-2.24 
Within 7-days (85th)  1.12 0.74-1.70 
Within 14-days (95th)  1.05 0.74-1.49 
Abbreviations: PC, palliative care, TPCC, triggered palliative care consultation 
†: Significant at the p=.05 level 
‡: Significant at the p=.01 level 
NOTE. All regression analyses controlled for differences in age, race, sex, insurance, cancer type, cancer 
stage, PC consultation in a prior hospital encounter, hospitalization in prior 30 days, comorbidities, 
discharge status, and a linear time trend. Length of stay was included as an exposure variable. 
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CHAPTER 6.  INPATIENT PALLIATIVE CARE CONSULTATION AND 30-DAY 
READMISSIONS IN ONCOLOGY  
Overview 
Prior research indicates that hospice and palliative care delivered in outpatient 
settings are associated with reduced hospital readmissions for cancer patients. However, little 
is known about how inpatient palliative care affects readmissions in oncology. The objective 
of this study was to examine associations among inpatient palliative care consultation, 
hospice use (discharge), and 30-day readmissions among patients with solid tumor cancers. 
We identified all live discharges from a large tertiary cancer hospital between 2010 
and 2016. Palliative care consult data were abstracted from medical charts and linked to 
hospital encounter data. Propensity scores were used to match palliative care consult to usual 
care encounters. Modified Poisson regression models estimated adjusted relative risk (aRR) 
and 95% confidence intervals (CI) of 30-day readmissions and hospice discharge. We 
compared predicted probabilities of readmission for palliative care consultation with hospice 
discharge, without hospice discharge, and usual care. 
Of 8,085 eligible encounters, 753 involved a palliative care consult. The likelihood of 
having a 30-day readmission did not differ between palliative care consult and usual care 
groups (p>.05). However, the palliative care consult group was more likely than usual care to 
have a hospice discharge (aRR = 4.09, 95% CI: 3.07-5.44). The predicted probability of 30-
day readmission was lower when palliative care consultation was combined with hospice 
discharge compared to consultation with discharge to non-hospice post-acute care or usual 
care (p<.001). 
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The effect of inpatient palliative care on readmissions in oncology is largely driven 
by hospice enrollment. Strategies that combine palliative care consultation with hospice 
discharge may decrease hospital readmissions and improve cancer care quality.  
Introduction  
Many cancer patients experience poor symptom control and aggressive treatment near 
the end of their lives, including hospitalizations and emergency department (ED) visits, with 
limited medical benefits.1-4 Unplanned 30-day hospital readmission rates as high as 27% 
have been reported in patients with cancer.5 Reducing unplanned 30-day readmissions is 
important to patients and healthcare organizations seeking to lower overall healthcare costs 
and avoid financial penalties under the federal Hospital Readmissions Reduction Program.6 
Although cancer hospitals currently are excluded from this penalty, frequent hospital 
readmissions and ED visits remain important for oncology patients and are well-accepted 
indicators of poor-quality care for cancer patients near the end of life.1,7 Prior research 
indicates hospice use is associated with reduced hospital readmissions among cancer 
patients,3,5 yet conversations about hospice often do not occur between cancer patients and 
their providers.8 As a result, cancer patients frequently do not enroll in hospice or are referred 
late in the disease trajectory.9  
Palliative care has also been shown to decrease hospitalizations and ED visits among 
cancer patients when delivered in outpatient settings.10-13 In inpatient settings, palliative care 
reduces the intensity of hospital treatment, and thus reduces the cost of hospital care.14,15 
However, less is known about how inpatient palliative care affects readmissions in oncology. 
Therefore, using a propensity-matched cohort from a large tertiary cancer hospital, we 
examined associations among inpatient palliative care consultation, hospice use (discharge), 
and 30-day unplanned readmissions. We hypothesized that inpatient palliative care 
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consultation would be associated with greater hospice discharge and reduced 30-day 
readmissions. To further understand the mechanism by which inpatient palliative care may 
reduce readmissions, we also explored whether inpatient palliative care consultation 
combined with hospice discharge was associated with reduced 30-day readmissions. 
Methods 
Sample 
We conducted a retrospective cohort study of all patients who were admitted and/or 
discharged from the medical oncology or gynecologic oncology service lines at University of 
North Carolina (UNC) Hospitals (an 804-bed acute care facility and National Cancer 
Institute-designated Comprehensive Cancer Center) from January 1, 2010, to June 30, 2016. 
We included all live discharges with a solid-tumor diagnosis documented during the hospital 
stay based on International Classification of Diseases (ICD) 9 and 10 codes (see Data 
Supplement). If multiple palliative care consults occurred during an encounter, we only 
included the first one. We excluded 69 palliative care consults that were initiated in a service 
other than the admitting and/or discharge service (e.g., originated in medical intensive care 
but the admitting and/or discharge service was medical oncology). 
The unit of analysis was the discharge encounter for hospitalization. All eligible 
encounters included in the sample were considered to be an index admission. Encounters 
with a discharge status of missing, “left against medical advice,” or deceased were excluded 
as an index admission but could be considered a readmission. A readmission could also serve 
as an index admission for subsequent discharge encounters.  
UNC Hospital Inpatient Palliative Care Consultation Service 
The inpatient palliative care consult team service at UNC Hospital began in 2002. 
The team is interdisciplinary, composed of an attending palliative physician, two nurse 
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practitioners, a social worker, and a chaplain. Palliative care clinicians provide expert pain 
and symptom management, supportive services for spiritual/psychosocial distress, goal 
setting, and decision-making for inpatients at all stages of illness and their families. 
Consultation is available to patients by referral of the inpatient treating physician.  
Data Sources  
We obtained data on palliative care consults from the UNC Palliative Care Clinical 
Research database, which includes data abstracted from medical charts for all patients at 
UNC Hospital referred for palliative care consultation. This data source provided dates of 
service and referring oncology service. Using unique identifiers, we linked these data to 
hospital encounter data obtained from the Carolina Data Warehouse for Health (a central data 
repository containing clinical, research, and administrative data sourced from the institution 
electronic health record system; CDW-H). This data source provided admitting and discharge 
service and dates, discharge status, as well as clinical and demographic characteristics. The 
dataset was then augmented with information on patient cancer stage at diagnosis as a 
proximate indicator of disease extent during hospitalization obtained from the UNC Hospital 
Cancer Registry. The UNC Institutional Review Board reviewed and approved this study.  
Measures 
Outcomes. Our primary outcomes were hospice discharge (inpatient or home) and 30-
day unplanned all-cause readmissions. We defined readmission as an inpatient episode, 
including ED visits resulting in an admission, within 30 days of discharge. Secondary 
outcomes included ED visits not resulting in an admission within 30 days of discharge and a 
composite outcome of inpatient readmissions and ED visits within 30 days of discharge. We 
calculated time to readmission as the number of days between the index admission discharge 
date and readmission date.  
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Longer travel distance is an obstacle for accessing hospital care.16 As such, because 
our data sources were unique to only one hospital system, readmissions for patients whose 
residence was further away might be missed. To minimize potential measurement error, we 
used Hospital Referral Region (HRR) as a proxy for travel distance and restricted the sample 
to encounters with resident zip codes in the Durham, Raleigh, and Greensboro, North 
Carolina, HRRs. Admissions for chemotherapy or radiotherapy (identified using ICD codes 
V58.xx and Z51.xx), psychiatry, or rehabilitation services were not considered readmissions 
because these usually indicated a planned admission. 
Independent variable. The independent variable was whether or not an encounter 
involved a palliative care consultation. Encounters that involved a palliative care consult 
were included in the “treatment” group; encounters that did not involve palliative care 
consult were included in the “usual care” group. 
Covariate selection. We used propensity score matching (see below) to balance 
treatment and usual care groups on the following clinical and demographic covariates: race 
(White, Black, other, missing); sex; insurance status (private, Medicare, Medicaid, other 
public, uninsured, missing); palliative care consultation in a prior hospital encounter; 
hospitalization in the prior 30 days; solid-tumor cancer type (digestive, breast, bone/joint, 
soft tissue, skin, head/neck, urological, lung/thoracic, gynecological, other/ill defined, central 
nervous system, missing), oncology service (medical oncology or gynecologic oncology), 
and admission year. Age was included as a continuous variable. Stage of disease at diagnosis 
was based on the American Joint Committee on Cancer staging criteria (0 or 1, 2 or 3, 4). If 
stage could not be ascertained, it was categorized as “missing.” We assessed comorbidity 
illness (0, 1, 2 or more comorbidities) using previously described coding algorithms.17 
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Comorbidity ICD codes were derived from the patient’s problem list in the electronic health 
record system. The comorbidities in the electronic health record may be added any time 
patients receive care at the institution and are not associated with a specific encounter. We 
searched the problem list for evidence of comorbidities 30 days before and after the 
admission date to ensure all comorbidities present at the time of an encounter were captured.  
Propensity Score  
To minimize the potential for selection bias, propensity scores were used to identify 
encounters that did not involve a palliative care consult but were comparable to encounters 
that did involve a palliative care consult based on the aforementioned observed covariates.18 
We used a modified Poisson regression model19 with palliative care consult as the outcome 
and observed covariates as predictors to calculate propensity scores. Length of stay (number 
of calendar days between admission date to discharge date) was included as an exposure 
variable in the model to account for different observation periods. Robust standard errors 
clustered at the patient level were used to account for autocorrelation across encounters 
because some patients may have had multiple hospitalizations. Encounters that involved a 
palliative care consult were matched 1:1 to usual care encounters using the nearest neighbor 
with replacement method, which provided the smallest absolute standardized difference in 
covariates between the groups (i.e., <10%). Any covariates with a standardized difference 
greater than 10% were additionally adjusted for in the post-match analysis.  
Statistical Analysis 
Using the propensity score matched sample, we estimated the adjusted relative risk 
(aRR) and 95% confidence intervals (CI) of hospice discharge, 30-day unplanned all-cause 
readmission, and secondary outcomes (i.e., ED visits and a composite outcome of inpatient 
readmissions and ED visits) using modified Poisson regression models. For the readmission 
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analysis, we included days to death after discharge (number of calendar days between 
discharge date to death date) as the exposure to account for mortality during the 30-day 
readmission window. We used robust standard errors clustered at the patient level. We 
included hospice discharge as a covariate in the model when examining whether the 
combination of palliative care consultation with hospice discharge was associated with lower 
30-day readmissions. Adjusted predicted probabilities of a 30-day readmission for an 
encounter were then calculated to contrast outcomes for the following clinical scenarios: 
usual care, palliative consultation combined with hospice discharge, and palliative care 
consultation with discharge to non-hospice post-acute care (e.g., home with self-care or 
intermediate care facility). We conducted our analyses using Stata version 13.0 (College 
Station, TX). All statistical tests were two-tailed with a critical alpha equal to 0.05. 
Results 
Sample  
There were 9,760 discharge encounters from the medical oncology or gynecological 
oncology inpatient services. Of these, 1,341 had resident zip codes outside of the Durham, 
Raleigh, and Greensboro HRRs and 334 had a discharge status of missing, “left against 
medical advice,” or deceased. Of the 8,085 eligible discharge encounters, 753 involved a 
palliative care consult (Figure 6.1); 753 usual care propensity scored matched encounters 
were found (n=1,506), representing 1,081 distinct patients across the treatment and usual care 
groups. On average, patients had 2.4 discharges from the oncology inpatient services during 
the study period.  
The demographic and clinical characteristics of the unmatched and matched samples 
are presented in Table 6.1. The sample was predominantly White, male, and insured by 
Medicare. The mean age was around 60. Most encounters originated from the medical 
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oncology service. The unmatched sample indicated that compared to usual care, the palliative 
care consult group was more likely to be male, have a diagnosis of certain cancer types, have 
a palliative care consult in a prior hospital encounter, and be hospitalized in the prior 30 days. 
After matching, characteristics between the palliative care consult and usual care groups 
were similar (absolute standardized difference of less than 10%). However, the palliative care 
consult group remained significantly more likely than usual care to have a palliative care 
consult in a prior hospital encounter (15.6% vs. 9.8%) and hospitalization in the prior 30 days 
(30.2% vs. 24.2%). Therefore, we adjusted for these covariates for in the post-match 
analysis.  
Associations among Inpatient Palliative Care Consultation, Hospice Discharge, and 30-
Day Readmissions 
Table 6.2 shows rates of hospice discharge and 30-day readmissions using the 
matched sample. Overall, inpatient readmission rates were high, with 21% and 25.5% of 
encounters resulting in a readmission within 30-days of discharge in the palliative care 
consult and usual care groups, respectively. However, the ED visit rates without admission 
within 30-days of discharge were only 3.9% and 5.7% for the palliative care consult and 
usual care groups, respectively.  
In the adjusted analysis, the likelihood of having an inpatient readmission, ED visit, or 
composite outcome of an inpatient readmission and ED visit within 30 days of discharge did 
not significantly differ between the palliative care consult and usual care groups (p>.05). 
However, the palliative care consult group was significantly (p<0.001) more likely than usual 
care to have a hospice discharge (38% vs 9.2%; aRR = 4.09, 95% CI: 3.07-5.44) (Table 6.2).  
The adjusted predicted probability of an inpatient readmission was significantly (p<0.001) 
lower when palliative care consultation was combined with hospice discharge (5.8%), 
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compared to usual care (25.3%) or palliative care consultation with discharge to non-hospice 
post-acute care (29.4%). Likewise, the predicted probability of an inpatient readmission or 
ED visit was significantly (p<0.001) lower when palliative care consultation was combined 
with hospice discharge (8.9%), compared to usual care (31%) or palliative care consultation 
with discharge to non-hospice locations (34%). Across all comparisons, we found no 
differences (p>.05) in the predicted probability of an ED visit (Table 6.3).  
Discussion 
This study examined associations among inpatient palliative care consultation, 
hospice use, and 30-day unplanned readmissions among patients with solid tumors admitted 
to oncology services. After propensity score matching, we found palliative care consult and 
usual care groups had similar likelihoods of 30-day readmissions, including any return to 
acute care, defined as inpatient readmission or ED visit. However, consistent with our 
hypothesis, the palliative care consult group was over four times more likely than usual care 
to have a hospice discharge. This finding is consistent with prior research indicating earlier 
and more frequent hospice use among cancer patients when specialty palliative care 
augments oncology care.20-24 When examined more closely, palliative care consultation 
combined with hospice discharge had a much lower probability of inpatient readmission or 
ED visit (combined) compared to palliative care consultation in the absence of hospice 
discharge or usual care. This was also true for inpatient readmissions. Our findings extend 
prior research demonstrating the effect of inpatient palliative care consultation on 
readmissions is largely driven by hospice enrollment;25-27 we provide important insights into 
the mechanism by which inpatient palliative care consultation may reduce 30-day 
readmissions in oncology. For example, using a propensity score matched sample, Tangeman 
et al. found a similar likelihood of 30-day readmissions among inpatient palliative care and 
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usual care patients. However, only 1.1% of inpatient palliative care patients discharged to 
hospice experienced a readmission compared to 6.6% of usual care patients (p<.01).27 
Likewise, among patients who received an inpatient palliative care consultation, Enguidanos 
et al. found that patients discharged home with self-care were 3.7 times more likely to be 
readmitted within 30-days of discharge compared to patients discharged with hospice or 
home-based palliative care (p<.05).25 Thus, our study adds to evidence supporting outpatient 
palliative care services, including hospice, as support for patients with serious illness to 
manage their persistent symptom distress and rapid changes in health. Additional research 
elucidating the relationship between inpatient palliative care consultation, continuity of care 
in the outpatient setting, and readmissions in oncology is needed.  
The findings also speak to the importance of enhancing collaboration and care 
coordination between inpatient palliative care and hospice or other outpatient palliative care 
specialty services. Cancer patients near the end-of-life are often faced with the decision to 
pursue comfort treatment and transition to hospice. Palliative care teams play an active role 
in patients’ decision-making process about hospice enrollment, including dispelling myths 
that hospice hastens death or is appropriate only in the finals days of life.28 As our findings 
suggest, inpatient palliative care consultations are key to initiating goals of care and 
advanced care planning discussions in order to bridge these difficult transitions from 
hospitalization to hospice for cancer patients.  
There are several limitations to this study. First, it was conducted at a single academic 
medical center with an established inpatient palliative care consultation service. As such, this 
limits generalizability. Second, we only included readmissions to one hospital system, which 
may underestimate readmissions. We attempted to address this limitation by including 
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resident zip codes and neighboring HRRs as a proxy for travel distance. Of note, we 
conducted the analysis on the full sample and the findings were similar. Third, although 
selection bias was minimized through propensity score matching, we cannot rule out the 
possibility of unobserved confounding. Instrumental variables could potentially address 
unobserved confounding, but we were unable to identify a valid instrumental variable for this 
sample. Fourth, we lacked data on the “active ingredients” of palliative care consultations 
(e.g., goals of care and treatment decision-making, symptom management, or other elements 
important in the choice for hospice). Identifying components of palliative care consultation 
and their delivery by specialty palliative care versus oncology providers is an important area 
for future research. 
Despite these limitations, this study makes an important contribution to understanding 
the role of inpatient palliative care consultation in mitigating use of low benefit, high cost 
treatments by increasing hospice use and reducing 30-day readmissions in oncology. To date, 
little is known about how hospitals can best achieve reductions in readmissions in 
oncology.3,29,30 However, studies focusing on associations between inpatient palliative care 
consultation and both hospice use and 30-day readmissions in oncology are limited.31 Using a 
large sample of hospitalizations across multiple cancer types, our study is the first to 
demonstrate inpatient palliative care consultation can achieve a significant decrease in 30-
day readmissions in oncology mostly through combining consultation with hospice 
discharge. Considering prior research which shows cancer inpatients underuse palliative care 
services,20,32,33 our findings have important implications for the need to develop strategies 
that promote palliative care consultation and earlier introduction of hospice in inpatient 
oncology.  
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Figure 6.1. Study sample flow diagram. 
 
  
Total admissions and/or discharges 
from medical oncology and 
gynecologic oncology services at UNC 
Hospital with a diagnosis of solid 
tumor cancer 
N=9,760 Excluded as index admissions: 
N=1,341 encounters with resident zip 
codes outside of Durham, Greensboro, 
Raleigh, NC, HRRs 
 
N=334 encounters missing discharge 
status (N=17), left against medical 
advice was discharge status (N=18), 
or deceased at discharge (N=299) 
N= 69 excluded palliative care 
consults 
Total eligible 
encounters available for 
propensity score  
N=8,085 
Total encounters with a 
palliative care consult  
 
N=753 
Total usual care 
propensity score 
matched encounters 
N=753 
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Table 6.1. Description of Sample by Palliative Care Consult Status, Matched (N=1,506) and 
Unmatched (N=8,085) 
 
 
 
 
Variables 
 
 
 
PC 
Consulted 
(n=753) 
Unmatched  Matched 
 
 
Usual 
Care  
(n=7,332) 
 
Absolute 
Standardized 
Difference 
(%) 
  
 
 
Usual Care 
(n=753) 
 
Absolute 
Standardized 
Difference 
(%) 
Age, mean (SD) 58.6 58.5 0.4  59.3 5.6 
Race (%)                 
White 
  Black 
Other 
 Missing 
 
60.3 
29.6 
8.0 
2.1 
 
62.2 
28.8 
7.5 
1.5 
 
3.9 
1.7 
1.7 
4.5 
  
58.2 
29.9 
9.3 
2.6 
 
4.3 
0.6 
5.0 
4.0 
 
Sex: Female (%) 
 
24.2 
 
31.9 
 
17.2 
  
27.5 
 
7.4 
Insurance (%) 
Medicare 
Medicaid 
Other Public 
Uninsured 
Private 
Missing 
 
41.7 
18.3 
3.7 
1.8 
30.3 
4.1 
 
40.6 
19.1 
2.9 
2.6 
31.0 
3.8 
 
2.2 
2.1 
4.7 
5.1 
1.7 
1.7 
  
44.5 
16.7 
3.3 
1.8 
29.3 
4.4 
 
5.6 
4.1 
2.2 
0.0 
2.0 
1.4 
Cancer Type (%) 
Digestive: Yes 
Breast: Yes 
Bone/Joint: Yes 
Soft Tissue: Yes 
Skin: Yes 
Head/Neck: Yes 
Urological: Yes 
Lung/Thoracic: Yes 
Gynecological: Yes 
Other/Ill Defined: Yes 
CNS: Yes 
Missing: Yes 
 
46.5 
6.4 
23.6 
2.5 
5.6 
1.5 
5.8 
31.3 
30.0 
23.7 
12.6 
5.4 
 
32.4 
7.9 
16.3 
2.8 
2.5 
3.5 
5.4 
25.7 
27.3 
15.4 
10.8 
8.8 
 
29.0 
6.1 
18.5 
1.9 
15.6 
13.2 
2.1 
12.4 
5.9 
21.2 
5.6 
13.0 
  
47.9 
7.2 
23.2 
2.0 
4.5 
1.6 
5.7 
28.9 
26.2 
22.8 
12.3 
4.0 
 
3.0 
3.1 
1.0 
3.3 
5.4 
0.9 
0.6 
5.3 
8.5 
2.4 
0.8 
5.7 
Cancer Stage (%) 
0 or 1 
2 or 3 
4 
Missing 
 
8.6 
33.5 
23.6 
34.1 
 
11.3 
29.1 
24.3 
35.3 
 
9.0 
9.8 
1.6 
2.4 
  
9.4 
35.4 
23.1 
32.1 
 
2.8 
4.0 
1.2 
4.2 
Comorbidities: Charlson 
Index (%) 
0 
1 
>=2 
 
 
70.9 
18.1 
10.8 
 
 
72.9 
16.7 
10.4 
 
 
3.6 
4.0 
1.5 
  
 
66.0 
20.5 
13.5 
 
 
9.7 
6.3 
8.6 
Length of Stay, mean 
days (SD) 
 9.6 (8.9) - -  10.5 (9.2)  
Days to death post 
discharge, mean days 
(SD)† 
13.9 (8.5) - -  14.0 (8.2) - 
PC Consulted During a 
Prior Hospitalization: Yes 
(%)* 
 
15.6 
 
3.9 
 
40.2 
  
9.8 
 
20.0 
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Hospitalized in Prior 30 
days: Yes (%)* 
 
30.2 
 
22.5 
 
17.6 
  
24.2 
 
13.9 
Service (%) 
             Medical 
Oncology 
Gynecologic Oncology 
 
53.5 
46.4 
 
60.8 
39.2 
 
14.8 
14.8 
  
56.6 
43.4 
 
6.2 
6.2 
Year of Encounter (%) 
2010 
2011 
2012 
2013 
2014 
2015 
2016 
 
10.8 
15.5 
13.6 
12.8 
15.4 
17.1 
14.6 
 
16.3 
18.3 
15.9 
16.2 
13.4 
12.5 
7.4 
 
16.1 
7.4 
6.5 
9.4 
5.7 
13.0 
23.3 
  
10.6 
15.0 
14.6 
13.5 
16.1 
16.1 
14.1 
 
0.6 
1.4 
2.6 
1.9 
1.9 
3.0 
1.7 
Abbreviations: PC, palliative care, SD standard deviation, CNS, Central Nervous System 
*Covariates with standardized difference >10% were adjusted for in the post-match analysis. 
† Calculated for 349 encounters in the matched sample where a death date was recorded within 30 days of 
discharge date. 
 
 
Table 6.2. Associations among Palliative Care Consultation, Hospice Discharge, and 30-Day 
Readmissions in Inpatient Oncology 
 
 
Outcome Variables 
 
Palliative Care 
Consulted 
(n=753) 
 
 
Usual Care 
(n=753) 
 
 
Adjusted  
Relative Risk (95% CI) 
Discharge to hospice, n (%) 286 (38.0) 69 (9.2) 4.09 (3.07-5.44)‡ 
Inpatient readmission 30 days 
after discharge, n (%) 
158 (21.0) 192 (25.5) 0.93 (0.76-1.13) 
ED visit 30 days after discharge, 
n (%) 
29 (3.9) 43 (5.7) 0.76 (0.46-1.24) 
Inpatient readmission or ED visit 
30 days after discharge, n (%) 
187 (24.8) 235 (31.2) 0.89 (0.75-1.07) 
Abbreviations: ED, emergency department, CI, confidence interval 
Note.  Regressions adjusted for palliative care consult in a prior hospital encounter and hospitalization in 
the prior 30-days.  
†p<.001 
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Table 6.3. Adjusted Predicted Probabilities and 95% CIs of 30-day Readmission Outcomes in 
Inpatient Oncology: Palliative Care Consultation Combined with Hospice Discharge vs. 
Discharge to Non-Hospice Post-Acute Care and Usual Care 
 
 
Outcome Variables 
 
 
Usual Care 
(N=753) 
 
Palliative Care Consulted  
(without hospice) 
(N=753) 
Palliative Care 
Consulted 
(with hospice) 
(N=753) 
Inpatient readmission 30 
days after discharge  
25.3% (0.22-0.29) 29.4% (0.25-0.33) 5.8% (0.03-0.09)† 
ED visit 30 days after 
discharge 
5.5% (0.04-0.07) 4.6% (0.03- 0.06) 2.9% (0.01-0.05) 
Inpatient readmission or 
ED visit 30 days after 
discharge 
31.0% (0.27-0.35) 34.0% (0.30-0.38) 8.9% (0.05-0.126)† 
Abbreviations: ED, emergency department 
Note. regression adjusted for hospice discharge, palliative care consult in a prior hospital encounter, 
hospitalization in the prior 30-days. 
†p<.001 
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CHAPTER 7. SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE, AND RESEARCH 
Summary of Findings 
The purposes of this research were to: (1) gain a greater understanding of the 
organization-level determinants associated with effective palliative care consult 
implementation in oncology and (2) examine whether inpatient palliative care consults 
improved health resource use (i.e., greater hospice discharge and reduced readmissions). The 
first study used a two-case study design and mixed-methods approach to examine the 
organizational context for palliative care consult implementation in two organizational 
settings (medical oncology and gynecologic oncology service lines). We drew on the Klein 
and Sorra Organizational Theory of Innovation Implementation1,2 as a guide for developing 
our interview guide and interpreting our results. To date, the theory has contributed to 
important insights regarding the influence of organizationally-sanctioned formal 
implementation policies and practices (IPPs) on effective implementation of healthcare 
innovations, however the role of informal IPPs has been largely unexplored.1-6 We used 
palliative care consultation in inpatient oncology as a model to examine formal and informal 
IPPs as determinants of innovation implementation.  
Our study was the first to provide an in-depth exploration of the organizational 
context for palliative care consult implementation in inpatient oncology. The study’s key 
finding was empirical support for the role of formal and informal IPPs as determinants of PC 
consult implementation in inpatient oncology. Specifically, despite the medical oncology 
service’s use of multiple formal IPPs (e.g., training, clinician prompting, chart review, top-
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down approach), most participants were unaware of the IPPs, which contributed to a weak 
implementation climate. In contrast, the gynecologic oncology service employed only one 
formal IPP (i.e., written guideline) and instead relied on multiple informal IPPs (e.g., 
spontaneous feedback/encouragement, on-the-job training, bottom-up approach), which 
contributed to broader clinician awareness and a strong implementation climate. Although 
preliminary, this study makes a novel contribution by refining the Organizational Theory of 
Innovation Implementation to suggest that IPPs can be conceptualized as formal and 
informal. Specifically, relying solely on organizationally sanctioned formal IPPs may not be 
effective in creating a strong and sustainable climate for implementation in busy, complex 
healthcare organizations such as the academic oncology services examined in this 
dissertation.7 From a theoretical standpoint, our findings support the idea that informal IPPs 
may compensate or substitute for formal IPPs. For example, spontaneous 
feedback/encouragement among clinicians could provide instrumental social support that 
substitutes for a formal training program. However, this substitution may be more likely to 
occur in smaller healthcare organizations where there is greater opportunity for social 
interaction and information sharing. Finally, this study also added to the existing literature 
demonstrating the utility of this theory for understanding the implementation of innovations 
in healthcare organizations.3-5,8 
The second study used difference-in-difference estimation to further examine the 
organization-level determinants of palliative care consult implementation in inpatient 
oncology. A promising organizational approach for promoting implementation is triggered 
palliative care consultation (TPCC). For the second study, the single formal IPP employed in 
gynecologic oncology and multiple formal IPPs employed in medical oncology described 
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previously were operationalized as two TPCC approaches for palliative care consult 
implementation. To evaluate the impact of the two TPCC approaches on uptake and 
timeliness of consult implementation, we linked palliative care consult data abstracted from 
medical charts to hospital encounter data. We hypothesized that TPCC supported by multiple 
strategies in medical oncology would be associated with greater uptake and decreased time to 
consult compared to a single strategy in gynecologic oncology. We also hypothesized that 
TPCC supported by a single strategy would be superior to usual care (i.e., pre-TPCC 
initiation in medical oncology service). The adjusted analyses showed that TPCC supported 
by a single strategy in gynecologic oncology was associated with greater palliative care 
consult uptake compared to usual care (aRR 1.45, p<.05), and TPCC supported by multiple 
strategies in medical oncology was associated with greater palliative care consult uptake 
compared to a single strategy (aRR 2.34, p<.001). Across all comparisons, we found no 
association between TPCC and time to palliative care consult (p>.05).  
The third study used a propensity matched cohort to examine associations among 
inpatient palliative care consultation, hospice use (discharge), and 30-day unplanned 
readmissions. We hypothesized that inpatient palliative care consultation would be associated 
with greater hospice discharge and reduced 30-day readmissions compared to “usual care” 
(no palliative care consultation). To further understand the mechanism by which inpatient 
palliative care may reduce readmissions, we also examined whether inpatient palliative care 
consultation combined with hospice discharge (inpatient or home) was associated with 
reduced 30-day readmissions. Secondary outcomes included ED visits not resulting in an 
admission within 30 days of discharge and a composite outcome of inpatient readmissions 
and ED visits within 30 days of discharge. In the adjusted analysis, the likelihood of having a 
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30-day readmission did not significantly differ between the palliative care consult and usual 
care groups (p>.05). However, the palliative care consult group was significantly (p<0.001) 
more likely than the usual care group to have a hospice discharge (38% vs 9.2%; aRR = 
4.09). The adjusted predicted probability of 30-day readmission was significantly lower 
when palliative care consultation was combined with hospice discharge compared to usual 
care or palliative care consultation with discharge to non-hospice locations (p<.001). Our 
findings extend prior research demonstrating the effect of inpatient palliative care 
consultation on readmissions is largely driven by hospice enrollment; 9-11 we provide 
important insights into the mechanism by which inpatient palliative care consultation may 
reduce 30-day unplanned readmissions in oncology.9-11  
Practice Implications 
The main findings from this dissertation were that TPCC improved consult 
implementation in oncology and that inpatient palliative care consults leading to hospice 
discharge resulted in reduced 30-day readmissions. However, the findings from the first 
study suggest healthcare systems should consider the organizational context for palliative 
care consult implementation to identify the optimal strategies for integrating palliative care 
consults into oncology practice. Specifically, the second study suggested that TPCC 
supported by multiple strategies had the greatest impact on uptake. On the other hand, in 
certain contexts (i.e., healthcare settings led by a small and unified team) a single-strategy 
approach may provide adequate support for creating a strong implementation climate for 
palliative care consults and subsequent effective implementation.  
In addition, to address high cost of hospital readmissions, in 2010 the Affordable 
Care Act included a provision for Centers for Medicare and Medicaid Services (CMS) to 
reduce its payments to hospitals with excessive readmissions under the Hospital 
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Readmissions Reduction Program.12 Under this program, hospitals are fined for high 30-day 
readmissions rates. Although CMS currently excludes cancer diagnoses from this penalty and 
there is no standardized definition of an avoidable hospitalization within the context of 
cancer,13 frequent readmissions and emergency department visits among cancer patients are 
well-accepted indicators of poor-quality care for cancer patients near the end of life.14,15 As 
our findings suggest, inpatient palliative care programs in oncology are key to initiating goals 
of care and advanced care planning discussions in order to bridge these difficult transitions 
from hospitalization to hospice for cancer patients, thereby reducing 30-day readmissions and 
attaining better quality cancer care. 
Policy Implications 
The findings from the second study showed 8.8% of medical oncology and 11.0% in 
gynecologic oncology encounters involved a palliative care consultation, which is consistent 
with the national goal to provide palliative care consults to approximately 10% of all 
hospitalized patients.16 Our palliative care consultation rate was also comparable to what has 
been reported in similar cohorts of hospitalized cancer patients,17,18 although variable rates 
have been reported ranging from 5% of patients hospitalized with head and neck cancer19 to 
24% in an inpatient gynecologic oncology service.20 However, no benchmark criteria for 
rates of palliative care consultation currently exists specific to inpatient oncology. 
Benchmarking refers to comparing clinical performance of a practice to an external standard 
or requirement.21 From a policy perspective, by establishing benchmark criteria, hospitals 
could leverage this information to determine the current rate of palliative care consultation, 
decide whether TPCC is needed, and evaluate the impact of TPCC on consult uptake.22  
In addition, contrary to our hypothesis, TPCC did not result in earlier timing of 
consultation that would be expected to enhance quality of care outcomes. Although there are 
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currently no clinical guidelines regarding the timing of palliative care consultation in 
inpatient oncology,23 earlier consults have greater benefit and are considered an important 
indicator of high-quality care.24 Additional efforts are needed to develop such guidelines and 
examine the potential impact of quality improvement efforts, such as lean methodology,25 to 
improve timeliness of consults. 
Finally, access to inpatient palliative care consults in oncology can be further 
strengthened by developing a well-trained palliative care workforce.26 In particular, TPCC 
has the potential to more efficiently allocate scarce resources in a healthcare system, which is 
often an issue given the workforce shortage of palliative care specialists.27 Alternatively, 
TPCC could increase demand beyond the ability of existing palliative care programs to 
respond and thus compromise quality of care. As such, policy mechanisms are needed that 
support increased funding and support for palliative medicine fellowship training programs 
or development of new structures by which practicing oncologists can obtain additional 
training in palliative medicine.27  
Research Implications 
There are a number of areas for future research that arose from this dissertation. The 
first study indicated more research is needed investigating refinement of the Organizational 
Theory of Innovation Implementation to include both formal and informal IPPs in shaping a 
strong implementation climate and subsequent effective implementation of healthcare 
innovations. For example, to increase generalizability of these findings, this work would 
need to be conducted in multiple locations and across diverse clinical practice settings. 
Future research could also include a quantitative measure of implementation climate, which 
would allow for a more precise comparison of this construct across healthcare organizations. 
In addition, although the second study did not find an association between TPCC and timing 
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of consultation, TPCC may have influenced other important aspects of implementation 
quality that we were unable to measure.28 For example, we were unable to assess quality of 
the consult (e.g., provision of both symptom management and advanced care planning, skill 
with which the consult was done). Future research should consider investigating the effect of 
TPCC on these additional quality indicators. How the strategies affect the sustained use of 
palliative care consults also remains to be investigated. The findings from the third study add 
to evidence supporting outpatient palliative care services, including hospice, as support for 
patients with serious illness to manage their persistent symptom distress and rapid changes in 
health. Additional research elucidating the relationship between inpatient palliative care 
consultation, continuity of care in the outpatient setting, and readmissions in oncology is 
needed. Finally, this study lacked data on the “active ingredients” of palliative care 
consultations, which might include goals of care and treatment decision-making, pain and 
symptom management, or other elements important in the choice for hospice. Components of 
palliative care consultation and their delivery by specialty palliative care physicians versus 
oncology providers is an important area for future research.  
Conclusions 
The overall objectives of this research were to determine whether TPCC could 
achieve effective palliative care consult implementation in oncology and to examine the 
effect of palliative care consults on health resource use. This was accomplished by pursuing 
three aims that used mixed-methods to explore the organizational context, implementation 
effectiveness, and clinical outcomes of palliative care consults in oncology. Using 
implementation of inpatient palliative care consults as a model, we found evidence for the 
role of both formal and informal IPPs as determinants of innovation implementation, 
suggesting refinements to organization theory. Further, we found TPCC is an effective 
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organizational approach for promoting inpatient palliative care consult implementation in 
oncology, with TPCC supported by multiple strategies having the greatest impact on uptake. 
Finally, inpatient palliative care consults leading to hospice discharge resulted in reduced 30-
day readmissions. Our results can be used to inform new policies and clinical practices that 
close the palliative care implementation gap in oncology and improve outcomes for cancer 
patients.   
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APPENDIX A. CANCER DIAGNOSIS CODES 
Cancer Type ICD-9 Code ICD-10 Code 
Digestive System Colorectal: 154.0 154.1 154.2 154.3 154.8 
153.0 153.1 153.2 153.3 153.4 153.5 153.6 
153.7 153.8 153.9 197.4 197.5  
Other Digestive: 150.0 150.1 150.2 150.3 
150.4 150.5 150.8 150.9 151 151.0 151.1 
151.2 151.3 151.4 151.5 151.6 151.8 151.9 
152 152.0 152.1 152.2 152.9 155 155.0 
155.1 156 156.0 156.1 156.2 156.9 157 
157.0 157.1 157.2 157.3 157.4 157.8 157.9 
158 158.0 158.8 158.9 159 159.8 159.9 
197.6 197.7 197.8 
Colorectal: C17.0 C17.1 C17.2 C18.0 
C18.1 C18.2 C18.3 C18.4 C18.5 
C18.7 C18.8 C18.9 C19.0 C20 C20.0 
C21.0 C21.1 C21.8 C78.4 C78.5  
Other Digestive: C15.3 C15.5 C15.9 
C16.0 C16.3 C16.4 C16.6 C16.8 
C16.9 C22.0 C22.1 C22.9 C23.0 C23 
C24.0 C24.1 C24.9 C25.0 C25.1 
C25.2 C25.3 C25.4 C25.7 C25.9 
C32.0 C78.6 C78.7 C78.89 
Breast 174.0 174.1 174.2 174.3 174.4 174.5 174.6 
174.8 174.9 175.9 
C50.212 C50.311 C50.411 C50.412 
C50.511 C50.512 C50.812 C50.911 
C50.912 C50.919 C79.81 
Urological 185 186.0 186.9 187.4 187.6 187.9 188.0 
188.2 188.4 188.6 188.7 188.8 188.9 189.0 
189.1 189.2 189.3 198.0 198.1 
C61 C62.11 C62.90 C62.92 C64.1 
C64.2 C64.9 C66.1 C67.2 C67.4 
C67.9 C68.0 C79.00 C79.01 C79.11 
C79.19 
Bones & Joints 170.0 170.1 170.2 170.3 170.4 170.6 170.7 
170.9 198.5 
C40.01 C41.0 C41.2 C41.4 C41.9 
C79.51 C79.52 
Soft Tissue 171.0 171.2 171.3 171.4 171.5 171.6 171.7 
171.8 171.9 176.1 176.2 176.0 176.4 164.0 
164.1 164.2 164.3 164.9 197.1 
C38.0 C38.1 C45.0 C45.1 C45.7 
C45.9 C48.0 C48.1 C48.2 C48.8 
C49.0 C49.21 C49.22 C49.3 C49.4 
C49.5 C49.6 C49.9 C78.1 
Skin 172.2 172.3 172.4 172.5 172.6 172.7 172.8 
172.9 173.3 173.4 173.5 173.6 173.7 173.8 
198.2 
C43.30 C43.20 C43.39 C43.4 C43.51 
C43.59 C43.60 C43.61 C43.70 
C43.71 C43.72 C43.9 C44.101 
C44.119 C44.221 C44.329 C44.40 
C44.42 C44.520 C44.529 C44.629 
C44.90 C44.91 C79.2 
Head and Neck 140.0 140.9 141.0 141.2 141.4 141.6 141.8 
141.9 142.0 142.2 142.9 143.1 144.0 144.8 
144.9 145.0 145.2 145.3 145.4 145.5 145.6 
145.8 145.6 145.9 146.0 146.7 146.8 146.9 
147.1 147.8 147.9 148.0 148.1 148.8 148.9 
149.0 149.8 161.8 161.9 195.0 
C01 C02.9 C04.9 C06.9 C09.9 C10.8 
C10.9 C11.9 C13.2 C13.9 C76.0 
C32.8 C32.9 
Gynecological 180.0 180.1 180.8 180.9 181 182.0 182.1 
182.8 183.0 183.2 183.4 183.8 183.9 184.0 
184.1 184.4 184.8 184.9 198.6 
C51.9 C52 C53.0 C53.9 C54.1 C54.9 
C55 C56.1 C56.2 C56.9 C57.00 
C57.01 C57.02 C57.4 C79.60 C79.61 
C79.62 
Lung/Thoracic 160.0 160.1 160.2 160.3 160.4 160.5 160.8 
160.9 161.0 161.1 161.2 162.0 162.2 162.3 
162.4 162.5 162.8 162.9 163.0 163.9 197.0 
197.2 197.3 
C34.00 C34.01 C34.10 C34.11 
C34.12 C34.2 C34.30 C34.31 C34.32 
C34.80 C34.81 C34.90 C34.91 
C34.92 C78.00 C78.01 C78.02 C78.2 
C78.39 C31.0 C31.1 C32.1 C32.2 
C79.31 C79.32 
CNS 191.0 191.1 191.2 191.3 191.4 191.6 191.7 
191.8 191.9 198.3 198.4 192.1 192.2 
C69-C72 C79.40 C79.49 
Other/Ill Defined 190.1 190.6 190.7 190.9 193 194.0 194.3 
195.1 195.2 195.3 195.5 195.8 196.0 196.1 
196.2 196.3 196.5 196.8 196.9 198.7 199.0 
199.1 199.2 
C73-C75 C76.1 C76.2 C76.3 C77.0 
C77.1 C77.2 C77.3 C77.4 C77.5 
C77.8 C77.9 C79.70 C79.71 C79.72 
C79.82 C79.89 C79.9 C80.0 C80.1 
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APPENDIX B. SEMI-STRUCTURED INTERVIEW GUIDE 
I. Implementation Policies and Practices (IPPs) refer to the plans, practices, structures, 
and strategies that an organization employs to put the innovation into place to support 
innovation use. 
• How do oncologists decide whether or not to refer a patient for inpatient 
palliative care consult at UNC Hospital?  
 Probe: What role do oncologists play?  
 Probe: What role do the palliative care clinicians play?  
Probe: What kinds of issues come up in obtaining an inpatient palliative care 
consult?  
 
• What are the criteria you use to decide on whether to refer a patient for an 
inpatient palliative care consult?  
 Probe: Who else is involved in that decision? 
 
• Have you received any education or training with regard to palliative care 
skills?  
Probes: Who provides it (UNC Hospital? Med E or gynecologic oncology?) 
How often? 
 
• Do you receive feedback on your performance regarding patient referrals for 
inpatient palliative care consults?  
  Probes: What kinds of feedback do you receive? How do you get that  
  feedback? How often do you get it? 
 
• What approaches or incentives are used by the inpatient Med E (solid tumor) 
(or gynecologic oncology) services to encourage you to refer patients for an inpatient 
palliative care consult?  
 
II. Implementation Climate refers to organizational members’ shared perceptions of 
implementation policies and practices in terms of their meaning and significance for 
innovation use. 
• Do you feel that referring patients for PC consult is something that is expected 
in the inpatient Med E (solid tumor) (or gynecologic oncology) services, or are there 
no expectations (meaning you can do it or not do it; it’s up to you)? 
 
• Do attending oncologists feel that there are major barriers or disincentives to 
referring patients for an inpatient palliative care consult? How about oncology 
residents and fellows? [for residents and fellows: Do you feel there are major barriers 
or disincentives to referring patients for an inpatient PC consult?) 
  Probe: What are some of the barriers (technological, EHR related)? 
• Do attending oncologists have a clear idea of why a patient should be referred 
for an inpatient palliative care consult? How about oncology residents and fellows? 
[for residents and fellows: do you have a clear idea of why a patient should be 
referred for an inpatient PC consult?] 
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  Probe: How clear of an idea is it? 
• Do attending oncologists know how inpatient palliative care consults work 
and what they entail (e.g., who’s responsible for what)? How about oncology 
residents and fellows? [for residents and fellows: do you know how inpatient PC 
consults work and what they entail?] 
  Probe: How do they work?  
  Probe: What do they entail? 
• Do attending oncologists know what they personally are supposed to do when 
referring a patient for inpatient palliative care consult and how they are supposed to 
do it? How about oncology residents and fellows? [for residents and fellows: do you 
know what you are personally supposed to do when referring a patient for inpatient 
PC consult and how you are supposed to do it?] 
  Probe: How do you know what you are supposed to do?  
  Probe: How do you know how to do it?  
• Do attending oncologists feel they have the knowledge, skills, and tools they 
need to play their part in referring patients for inpatient palliative care consults? Do 
attending oncologists feel that the residents and fellows has the knowledge, skills, and 
tools they need to play their part in the referring patients for inpatient palliative care 
consults? [Ask the questions conversely for residents and fellows]. 
Probe: Do the knowledge, skills, and tools you have help you? In what ways? 
 Probe: Do you have what you need? 
• Do attending oncologists feel enthusiastic about inpatient palliative care 
consults? How about oncology residents and fellows? [for residents and fellows: do 
you feel enthusiastic about inpatient PC consults?] 
 Probe: How enthusiastic are they? 
• Do attending oncologists here feel recognized and rewarded for referring 
patients for inpatient PC consults? How about oncology residents and fellows? [for 
residents and fellows: do you feel recognized and rewarded for referring patients for 
inpatient PC consults?] 
  Probe: What kinds of rewards or recognition do oncologists receive? 
  Probe: How are the rewards or recognition provided (e.g. by whom?) 
 
III. Innovation-Values Fit refers to the extent to which targeted employees perceive that 
innovation use will foster the fulfillment of their values. Values are concepts or beliefs 
that (a) pertain to desirable end-states or behaviors, (b) transcend specific situations, 
and (c) guide the selection and evaluation of behavior and events. 
• When you are on-service in Med E (solid tumor) (or gynecologic oncology) 
services, what are your top priorities?  
Probes: Delivering guideline concordant care? Timeliness of PC consults? 
Making sure no one dies? Making sure patient gets out of the hospital? 
Communication with patients’ outpatient oncologist? Making sure people are 
doing what they are supposed to be doing? 
Probe: Does referral to inpatient PC consults help you achieve your priorities 
or get in the way of your priorities? 
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• What do you perceive your role to be while you are on service in Med E (solid 
tumor) (or gynecologic oncology)? 
Probe: Is referral to inpatient PC consults consistent with your perceived role 
or does it conflict with your perceived role? 
 
IV. Rival activities are events or actions that compete with the innovation for attention, 
resources, or both.  
• Have any major events or changes occurred in the medical/gynecologic 
oncology service in the past year that may have impacted referrals for PC 
consultation? If so, what? What impact has this event or change had? 
 
V. Innovation champion 
• Are there particular oncologists in medical/gynecologic oncology who really 
stand out as champions of referring patients to inpatient palliative care consults? 
What do they do as champion? (By champion, I mean someone who goes above and 
beyond the call of duty, someone who is personally invested in improving quality of 
care for cancer patients) 
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APPENDIX C. COMORBIDITY DIAGNOSIS CODES 
Condition ICD-9 Codes ICD-10 Codes 
Acute Myocardial Infarction 410, 412 I21, I22, I252 
Congestive Heart Failure 428, 39891, 40201, 40211, 40291, 
40401, 40403, 40411, 40413, 
40491, 40493, 4254, 4255, 4257, 
4258, 4259 
I43, I50, I099, I110, I130, I132, 
I255, I420, I425, I426, I427, 
I428, I429, P290 
Peripheral Vascular Disease 0930, 4373, 440, 441, 4431, 4432, 
4438, 4439, 4471, 5571, 5579, 
V434 
I70, I71, I731, I738, I739, I771, 
I790, I792, K551, K558, K559, 
Z958, Z959 
Cerebrovascular Disease 36234, 430, 431, 432, 433, 434, 
435, 436, 437, 438 
G45, G46, I60, I61, I62, I63, 
I64, I65, I66, I67, I68, I69, H340 
Dementia 290, 2941, 3312 F00, F01, F02, F03, G30, F051, 
G311 
Chronic Pulmonary Disease 4168, 4169, 5064, 5081, 5088, 
490, 491, 492, 493, 494, 495, 496, 
500, 501, 502, 503, 504, 505 
J40, J41, J42, J43, J44, J45, J46, 
J47, J60, J61, J62, J63, J64, J65, 
J66, J67, I278, I279, J684, J701, 
J703 
Rheumatologic Disease 4465, 7100, 7101, 7102, 7103, 
7104, 7140, 7141, 7142, 7148, 
725 
M05, M32, M33, M34, M06, 
M315, M351, M353, M360 
Peptic Ulcer Disease 531, 532, 533, 534 K25,K26, K27, K28 
Mild Liver Disease 07022, 07023, 07032, 07033, 
07044, 07054, 0706, 0709, 5733, 
5734, 5738, 5739, V427, 570, 571 
B18, K73, K74, K700, K701, 
K702, K703, K709, K713, 
K714, K715, K717, K760, 
K762, K763, K764, K768, 
K769, Z944 
Diabetes without Complications 2500, 2501, 2502, 2503, 2508, 
2509 
E100, E101, E106, E108, E109, 
E110, E111, E116, E118, E119, 
E120, E121, E126, E128, E129, 
E130, E131, E136, E138, E139, 
E140, E141, E146, E148, E149 
Diabetes with Complications 2504, 2505, 2506, 2507 E102, E103, E104, E105, E107, 
E112, E113, E114, E115, E117, 
E122, E123, E124, E125, E127, 
E132, E133, E134, E135, E137, 
E142, E143, E144, E145, E147 
Hemiplegia or paraplegia 342, 343, 3341, 3440, 3441, 3442, 
3443, 3444, 3445, 3446, 3449 
G81, G82, G041, G114, G801, 
G802, G830, G831, G832, 
G833, G834, G839 
Renal disease 582, 585, 586, V56, 5830, 5831, 
5832, 5834, 5836, 5837, 5880, 
V420, V451, 40301, 40311, 
40391, 40402, 40403, 40412, 
40413, 40492, 40493 
N18, N19, N052, N053, N054, 
N055, N056, N057, N250, I120, 
I131, N032, N033, N034, N035, 
N036, N037, Z490, Z491, Z492, 
Z940, Z992 
Moderate or severe liver disease 4560, 4561, 4562, 5722, 5723, 
5724, 5728 
K704, K711, K721, K729, 
K765, K766, K767, I850, I859, 
I864, I982 
AIDS/HIV 042, 043, 044 B20, B21, B22, B24 
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APPENDIX D. AIM 2 SUPPLEMENTAL DATA 
Supplemental Table 1. Changes (difference-in-difference) in Palliative Care Consult 
Implementation Associated with Triggered Palliative Care Consultation: Single Strategy vs. 
Usual Care 
 
 Adjusted 
Relative Risk 
95% Confidence 
Interval 
Effects of TPCC on PC consult uptake (No=ref) 1.45‡ 1.05-2.01 
Age 1.00 0.99-1.00 
Race (White = ref) 
Black  
Other 
Missing 
 
1.02 
1.03 
1.53 
 
0.88-1.19 
0.77-1.39 
0.98-2.39 
Sex (Female = ref) 0.84 0.68-1.02 
Insurance (Medicare = ref) 
Medicaid 
Other Public 
Uninsured 
Private 
Missing 
 
0.90 
1.55† 
1.16 
0.96 
1.05 
 
0.72-1.12 
1.09-2.20 
0.74-1.81 
0.80-1.16 
0.71-1.54 
Cancer Type (No=ref for all types) 
Digestive 
Breast 
Bone/Joint 
Soft Tissue 
Skin 
Head/Neck 
Urological 
Lung/Thoracic 
Gynecological 
Other/Ill Defined 
CNS 
Missing 
 
1.45‡ 
0.89 
1.48‡ 
0.72 
1.50† 
0.90 
0.97 
1.27‡ 
0.88 
1.42‡ 
1.23 
0.91 
 
1.24-1.69 
0.67-1.17 
1.22-1.80 
0.47-1.11 
0.02-1.08 
0.50-1.63 
0.69-1.34 
1.06-1.52 
0.71-1.09 
1.20-1.69 
0.99-1.52 
0.65-1.26 
Cancer Stage at Diagnosis (Stage 0 or 1 = ref) 
Stage 2 or 3 
Stage 4 
Missing 
 
1.27 
1.27 
1.11 
 
0.98-1.65 
0.96-1.66 
0.87-1.45 
 
PC consultation in a prior hospital encounter (No = ref) 
 
2.74‡ 
 
2.19-3.41 
Hospitalized in Prior 30 days (No = ref) 1.27‡ 1.09-1.49 
Charlson comorbidity (0 = ref) 
1 
>=2 
 
1.07 
1.02 
 
0.90-1.28 
0.80-1.29 
Discharge Status (Alive = ref) 1.49 1.16-1.92 
PC: Palliative care 
TPCC: Triggered palliative care consultation 
CNS: Central nervous system 
†: Significant at the p=.05 level 
‡: Significant at the p=.01 level 
Note. Regression analyses also controlled for a linear time trend. Length of stay was included as an 
exposure variable. 
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Supplemental Table 2. Changes (difference-in-difference) in Palliative Care Consult 
Implementation Associated with Triggered Palliative Care Consultation: Multiple Strategies 
vs Single Strategy 
 
 Adjusted 
Relative Risk 
95% Confidence 
Interval 
Effects of TPCC on PC consult uptake (No=ref) 2.34‡ 1.57-3.49 
Age 0.99 0.99-1.00 
Race (White = ref) 
Black  
Other 
Missing 
 
1.02 
1.28 
0.87 
 
0.83-1.26 
0.90-1.81 
0.35-2.17 
Sex (Female = ref) 0.98 0.75-1.29 
Insurance (Medicare = ref) 
Medicaid 
Other Public 
Uninsured 
Private 
Missing 
 
0.73 
1.15 
 -- 
0.78 
0.84 
 
0.52-1.04 
0.72-1.84 
-- 
0.59-1.03 
0.49-1.43 
Cancer Type (No=ref for all types) 
Digestive 
Breast 
Bone/Joint 
Soft Tissue 
Skin 
Head/Neck 
Urological 
Lung/Thoracic 
Gynecological 
Other/Ill Defined 
CNS 
Missing 
 
1.74‡ 
0.81 
1.78‡ 
0.82 
1.58‡ 
1.05 
1.41† 
1.54‡ 
1.22 
1.42‡ 
1.31 
1.05 
 
1.42-2.12 
0.53-1.24 
1.39-2.29 
0.52-1.29 
1.15-2.19 
0.51-2.19 
1.01-1.98 
1.22-1.94 
0.85-1.76 
1.13-1.79 
0.89-1.93 
0.66-1.69 
Cancer Stage at Diagnosis (Stage 0 or 1 = ref) 
Stage 2 or 3 
Stage 4 
Missing 
 
1.31 
1.02 
0.86 
 
0.88-1.94 
0.67-1.56 
0.58-1.27 
 
PC consultation in a prior hospital encounter (No = ref) 
 
 
1.53‡ 
 
 
1.13-2.08 
Hospitalized in Prior 30 days (No = ref) 1.14 0.89-1.47 
Charlson comorbidity (0 = ref) 
1 
>=2 
 
1.06 
1.35† 
 
0.81-1.40 
1.00-1.81 
Discharge Status (Alive = ref) 1.49† 1.04-2.13 
PC: Palliative care 
TPCC: Triggered palliative care consultation 
CNS: Central nervous system 
†: Significant at the p=.05 level 
‡: Significant at the p=.01 level 
Regression analyses also controlled for a linear time trend. Length of stay was included as an 
exposure variable. 
 
 
